

UNIVERSITY OF PENNSYLVANIA -- SCHOOL OF MEDICINE
Curriculum Vitae

Date: May 2025

Donald L. Siegel, Ph.D., M.D.

Home Address: 2582 Brandon Court
Lansdale, PA 19446

Office Address: Division of Transfusion Medicine/3 Ravdin
Department of Pathology & Laboratory Medicine
HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA
3400 Spruce Street
Philadelphia, PA 19104-4283

Education: 1973-77 Sc.B. Brown University (Biophysics)
1977-83 Ph.D. Harvard University (Biophysics)
1983-87 M.D. University of Pennsylvania

Postgraduate Training and Fellowship Appointments:

1987-89 Resident in Clinical Pathology, HUP, Philadelphia, PA
1989-90 Chief Resident, Division of Laboratory Medicine, HUP,
Philadelphia, PA
1990-91 Fellowship, Transfusion Medicine, HUP, Philadelphia, PA
2007-08 Academic Medical Leadership Program, The Wharton School
of the University of Pennsylvania, Philadelphia, PA
2008-09 Penn Medicine Leadership Forum, The Wharton School of the
University of Pennsylvania, Philadelphia, PA

Faculty Appointments: 1987-89 Assistant Instructor, Dept. of Pathology & Lab.
Med., Univ. of PA School of Medicine, Philadelphia, PA
1989-91 Instructor, Dept. of Pathology & Lab.
Med., Univ. of PA School of Medicine, Philadelphia, PA
1991-92 Lecturer, Dept. of Pathology & Lab. Med.,
Univ. of PA School of Medicine, Philadelphia, PA
1992-00 Assistant Professor of Pathology & Lab. Med.,
Univ. of PA School of Medicine, Philadelphia, PA
2000-06 Associate Professor of Pathology & Lab. Med.,
Univ. of PA School of Medicine, Philadelphia, PA
2006- Professor of Pathology & Lab. Med.,
Univ. of PA School of Medicine, Philadelphia, PA

Hospital and Administrative Appointments:

1990-96 Hospital Transfusion Committee, Member, HUP
1991- Attending Physician, Blood Bank/Transfusion Medicine
Section, Department of Pathology & Lab. Medicine, HUP
1992-96 Vice-Chairman, Hospital Transfusion Committee, HUP

| | |
|---------------|---|
| 1997- | Attending Physician, Department of Pathology & Lab Medicine, Presbyterian Hospital |
| 2000- | Medical Director, AABB-accredited Blood Bank and Apheresis/Infusion Unit, Hospital of the University of Pennsylvania |
| 2000-2003 | Director, Blood Bank/Transfusion Medicine Section, Department of Pathology & Lab. Medicine, University of Pennsylvania Medical Center |
| 2000-present | Director, ACGME-accredited Fellowship Program in Blood Banking/Transfusion Medicine |
| 2000-present | Member for Oversight of Blood Usage, Clinical Effectiveness and Quality Improvement Committee |
| 2002--present | Member, Executive Committee, Department of Pathology & Lab Medicine |
| 2002-present | Medical Director, FACT-accredited cell collection and processing facilities for Hematopoietic Stem Cell Transplant Program |
| 2003-present | Founding Director, Division of Transfusion Medicine & Therapeutic Pathology |
| 2004-present | Member, Cell and Vaccine Production Facility Advisory Committee |
| 2006-07 | Member, General Clinical Research Center Advisory Committee |
| 2008-present | Medical Director, FACT-accredited Cell and Vaccine Production Facility |
| 2009-2017 | Medical Director, Penn Medicine Blood Donation Center |
| 2014-2017 | Medical Director for Cellular Therapies, Penn Medicine |
| 2017-present | Director, Clinical Cell & Vaccine Production Facility, Center for Advanced Cellular Therapeutics |
| 2024-present | Member, HUP Hospital Transfusion Committee |

Specialty Certification:

| | |
|------|---------------------------------|
| 1992 | The American Board of Pathology |
|------|---------------------------------|

Licensure:

Pennsylvania

Awards, Honors, and Membership in Honorary Societies:

| | |
|---------|---|
| 1977 | elected to Sigma Xi |
| 1977 | Honors in Biophysics, Brown University, undergraduate thesis: "Application of non-equilibrium thermodynamics to plasma membrane transport" |
| 1977-83 | NIH Pre-Doctoral Fellowship in the laboratory of Dr. Daniel Branton, Harvard University, Ph.D. dissertation: "Purification and characterization of human erythrocyte band 4.9, an actin bundling protein" |
| 1983 | Young Investigator Award, First Prize Recipient, Boston Blood Club, Harvard Medical School |

- 1983-85 Measey Foundation Scholar, University of Pennsylvania School of Medicine
- 1988 Two Young Investigator Awards, Academy of Clinical Laboratory Physicians and Scientists, 1988 Annual Meeting
- 1990 Berwick Resident Teaching Award, Department of Pathology & Laboratory Medicine, University of Pennsylvania
- 1991-92 Julius Erving Research Award of the Lupus Foundation of the Delaware Valley
- 1991-92 American Association of Blood Banks Research Award
- 1991-94 Clinical Investigator Award (K08), National Heart, Lung, and Blood Institute, NIH
- 1993-95 Basil O'Connor Scholar Research Award, March of Dimes Birth Defects Foundation
- 1996-97 National Blood Foundation Research Award
- 1996 National Blood Foundation Scholar
- 1998 Peter C. Nowell Teaching Award, Department of Pathology & Laboratory Medicine, University of Pennsylvania
- 2000 Leonard Berwick Memorial Teaching Award, University of Pennsylvania School of Medicine
- 2001 elected to John Morgan Society
- 2003 Philadelphia Antiques Show Proceeds Awardee, Board of Women's Visitors, University of Pennsylvania Medical Center
- 2003 Pennsylvania Biotechnology Greenhouse Award
- 2003 Christian R. and Mary F. Lindback Foundation Award for Distinguished Teaching, University of Pennsylvania
- 2010 Patient Health Care Hero awardee, Penn Medicine
- 2013 elected Fellow, College of American Pathologists
- 2013 elected to The Academy of Master Clinicians, Penn Medicine
- 2015 Patient Health Care Hero awardee, Penn Medicine
- 2016 UPenn Health System Quality & Patient Safety Award, "Blood Delivery and Wastage in the PeriOperative Setting"
- 2017 RISE (Research Innovation in Scientific Excellence) Award from AABB for best original research article published in *Transfusion* in 2016
- 2018 Francis S. Morrison, MD Memorial Lectureship, 2018 Meeting of the American Society for Apheresis
- 2018 Gift of Life Award, Ree Wynn TTP Foundation
- 2020 Patient Health Care Hero awardee, Penn Medicine
- 2020 Annual Honorary Lecturer Award, American Society for Apheresis
- 2020 Robert de Villiers Spiral of Life Award, Leukemia & Lymphoma Society, shared with team members Drs. June, Levine, Porter, Grupp, Frey, Maude, and Gill for CAR-T cell therapy
- 2020 Dale E. Smith Memorial Award, AABB
- 2020 2020 SITC Team Science Award, Society for Immunotherapy of Cancer
- 2021 Tibor Greenwalt Memorial Award and Lectureship, AABB
- 2021 "Startup of the Year" award for Vetigenics, LLC, Penn Center for Innovation

| | |
|------|--|
| 2022 | elected to Hall of Fame, National Blood Foundation, AABB |
| 2022 | National Press Ganey Pinnacle of Excellence Human Experience Award for Outpatient Practices – Apheresis Clinic, Clinical Practices of the University of Pennsylvania |
| 2023 | National Press Ganey Pinnacle of Excellence Human Experience Award for Outpatient Practices – Apheresis Clinic, Clinical Practices of the University of Pennsylvania |
| 2024 | National Press Ganey Pinnacle of Excellence Human Experience Award for Outpatient Practices – Apheresis Clinic, Clinical Practices of the University of Pennsylvania |
| 2024 | elected member of AABB Board of Directors |

Memberships in Professional and Scientific Societies:

Regional Committees:

Member, Medical Advisory Committee, Penn-Jersey Division of the American Red Cross (Member, 2000-present)
 Member, Executive Committee of the Medical Advisory Board, Penn-Jersey Division of the American Red Cross (2008-present)

Regional Scientific Committees:

Chair, Scientific Advisory Board, PhenoTech, Inc. (UPenn biotech start-up, 2003-2009)
 Chair, Scientific Advisory Board, Vetigenics, Inc. (UPenn biotech start-up, 2018-present)
 Chair, Scientific Advisory Board, Verismo Therapeutics, Inc. (2020-present)

National/International Societies:

American Association for Cell Biology (Member, 1981-present)
 American Association for the Advancement of Science (Member, 1987-present)
 AABB (Member, 1989-present)
 American Society of Hematology (Member, 1987-present)
 American Society for Apheresis (Member, 2001-present)
 John Morgan Society (Member, 2001-present)
 International Society for Cellular Therapy (Member, 2017-present)
 AABB, Board of Directors (2024-present)

National Scientific Committees:

Scientific Review Panel, Program Project on Prion Diseases, National Institute on Aging (Member, 1998)
 NIH/AABB-Sponsored Scientific Think Tank on “Setting the Research Agenda for Immunobiology in Transfusion Medicine” (Member, 1999)
 Scientific Subsection Committee, American Association of Blood Banks (Member, 1999-present)

Scientific Subcommittee on Hemoglobin/Red Cell, American Society of Hematology (Member, 1999-2003)
 Clinical Applications and Standards Committee, American Society for Apheresis (Member, 2004-present)
 NIH Hematology Small Business Activities (SBIR/STTR) Special Emphasis Panel Reviewer (2006)
 NIH NHLBI Strategic Planning Meeting “Research in Global Blood Safety and Availability, Domestic and International (Member, 2006)
 FDA Workshop on Molecular Methods in Transfusion Medicine (Member, 2006)
 Selected Topics in Transfusion Medicine Study Section (ZRG1 VH-E 50R, Member, 2010-)
 Board of Scientific Counselors, Site Visit, Department of Transfusion Medicine, NIH (Member, 2017)
 NIH NHLBI NITM NRSA Institution Research Training Grant (T32) Panel Reviewer (ad hoc member, 2019)
 NIH NHLBI NITM NRSA Institution Research Training Grant (T32) Panel Reviewer (standing panel member, 2020 - 2026)

International Scientific Committees:

4th International Workshop on Monoclonal Antibodies Against Human Red Blood Cells and Related Antigens, Paris (Coordinator, 1999-2001)
 Expert Review Panel for Evaluation of the Operational Research Program, Hema-Quebec, Quebec City, Canada (Member, 2004 and 2006)

Academic Committees at the University of Pennsylvania and Affiliated Hospitals:

1992-1996 Medical Student Advisor, School of Medicine
 1992-1998 Faculty Interviewer, Committee on Admissions, School of Medicine
 1994-present Faculty Advisory Committee, Transfusion Medicine Research Training Program (NIH T32 Award; member, 1994-1999, chair, 2000-present)
 1997-present Member, Immunology Graduate Group
 1997-present House Mentor, Combined Degree Mentoring Program, School of Medicine
 1998-present Member, Center for AIDS Research
 2000-present Member, Faculty Advisory Committee, Hemostasis/Thrombosis Research Training Program (NIH T32 Award)
 2000-present Member, Curriculum Committee for “Frontiers in Medical Science”
 2006-present Member, Institute for Translational Medicine and Therapeutics
 2008-2013 Member, Limited Application Selection Committee, School of Medicine
 2008-present Member, University of Pennsylvania Conflict of Interest Standing Committee
 2012-present Founding Member, Executive Committee, The Penn-CHOP Blood Center for Patient Care & Discovery

- 2013-present Member, Clinical Excellence Advisory Committee, Penn Medicine
- 2017-present Member, Center for Cellular Immunotherapies
- 2018-present Member, Glioblastoma Translational Center of Excellence, University of Pennsylvania

Major Teaching and Clinical Responsibilities for the University of Pennsylvania and Affiliated Hospitals:

- 1991-present Daily attending rounds, Blood Bank/Transfusion Medicine Section (until 2003); Division of Transfusion Medicine (2004-present); HUP; 3 months/year
- 1991-present In-service seminars on Transfusion Medicine topics to clinical services, HUP; throughout year
- 1991-present Morning report attending, Clinical Pathology Residents, HUP; 2 months/year
- 1991-present Seminars on Transfusion Medicine to rotating fellows, residents, medical students, HUP; throughout year
- 1992-1998 Pathology 200, lecturer (2 one-hour lectures on Transfusion Med.) and medical student section leader for Heme/Onc Bridge (4 two-hour meetings), School of Medicine (course now replaced by Curriculum 2000)
- 1992-1999 Immunology (ID101), lecturer (2 one-hour lectures on Immunohematology) and medical student section leader (5 hours/week x 4 weeks), School of Medicine (course now replaced by Curriculum 2000)
- 1992-present Course Director for Frontiers of Medical Science Course FRO505 (formerly Pathology 305), "Effective Use of Clinical Laboratory Tests", School of Medicine, course offered once per year for 2 weeks
- 1992-present Supervision of post-doctoral fellows and students in laboratory
- 1997-present Immunology 599, research seminar to Immunology Group graduate students, once/year
- 1998-present MDTI (Curriculum 2000), lecturer (2 one-hour lectures on Transfusion Medicine); medical student section leader for Transfusion Medicine laboratory (one three-hour session), School of Medicine
- 2000-present Course Director for Pathology elective, "Immunohematology" (Pathology 323), School of Medicine, offered each month
- 2000-present Didactics on Transfusion Medicine to Hematology/Oncology Fellows, HUP, twice per year
- 2000-present Director, Transfusion Medicine Journal Club (CME-accredited beginning in 2005)
- 2006-2010 Immunology course for Cell and Molecular Biology graduate group students, lecture on "Antibody-Based Techniques", once per year.
- 2006-present Blood Bank/Transfusion Medicine Overview for HUP anesthesiology residents
- 2006-present Lecture on "Phage Display Technology for Diagnostic and

- Therapeutic Reagents” in Masters in Translational Research course “Disease Measurement” (MTR603)
- 2006-present Medical Student Preceptor for “Longitudinal Experience to Appreciate Patient Perspectives (LEAPP) Course”
- 2007-present Faculty Preceptor for “Case Studies in Translational Medicine BIOM 510”
- 2007-2013 Faculty Preceptor for UPenn Medical Student Team Building initiative
- 2008-present Blood Bank Rotation Director for UPHS Anesthesiology and Critical Care residents
- 2008-present Apheresis for Nephrology Fellows
- 2010-2012 Lecture on “Changing Cells to Make Them Resistant to HIV” in Masters in Translational Research course “Translational Therapeutics” (MTR608)
- 2011-present Apheresis Rotation Director for HUP Renal Fellows
- 2011 Lecture on “*In vivo* and *in vitro* Generation of Antibodies” in Immunology course “Immune Responses” (IMUN508)
- 2011-2013 Faculty preceptor Roy and Diana Vagelos Program in Life Sciences and Management Program Capstone Course (LSMP 421)
- 2012-present “Technology Transfer, Intellectual Property, and Patents”, Pathology Resident Management Lecture Series, HUP, biannually
- 2012-present Didactics on Transfusion Medicine to Gyn/Onc Fellows, HUP, annually
- 2014-present Lecture “Cellular Therapies and Transfusion Delivery” in “Drug Delivery Systems: Targeted Therapeutics and Translational Nanomedicine” (CBE 564/PHARM 564)
- 2014-present Lecture “Phage Display and Other High Throughput Systems” in “Drug Delivery Systems: Targeted Therapeutics and Translational Nanomedicine” (CBE 564/PHARM 564)
- 2014-present Lecture “Translation: IP and Commercialization” in “Drug Delivery Systems: Targeted Therapeutics and Translational Nanomedicine” (CBE 564/PHARM 564)
- 2015-present Lecture “Apheresis for Heme/Onc Fellows”
- 2016-present Lecture “cGMP Manufacturing Facility Design and Infrastructure Considerations” in “Cell and Gene Therapy” (MTR/REG 621)
- 2016 Lecture “Identification of Cell-Surface Antigens” in “Molecular Imaging” (BE483/583)
- 2017 Lecture “Overview of Transfusion Medicine and the Appropriate Use of Blood Products”, Anesthesia/Critical Care Housestaff, Surgical Intensive Care Unit, HUP
- 2018-present Lecture “Cancer Immunotherapy” in “Personalized Medicine” (FRO531)
- 2020 Lecture “Passive Immunotherapy for SARS-CoV-2 Infection” in “Biotechnology, Immunology, Vaccines and COVID-19” (ENGR450/55)
- 2021-present Lecture “Transfusion Medicine” for Internal Medicine Residents, HUP

- 2025 Lecture "Overview of Blood Banking/Transfusion Medicine" for Transplant Fellows, HUP
- 2025 Lecture "Overview of Blood Banking/Transfusion Medicine" for Emergency Department Housestaff, HUP

Other Teaching:

- 1996-present Co-Director/Faculty, "Phage Display of Proteins and Peptides", Cold Spring Harbor Laboratory Course, Cold Spring Harbor, NY, two-week course given annually
- 2001 "Practical and technical issues regarding phage display technology," 4th International Workshop on Monoclonal Antibodies Against Human Red Blood Cells and Related Antigens, Paris, France
- 2009 "Workshop on construction and panning of antibody phage display libraries," 11th Annual Phage Display of Antibodies and Peptides, PEGS Protein Engineering Summit, Boston, MA.

Lectures by Invitation:

1. February, 1981 *The Red Cell Cytoskeleton*, Workshop at ICN Meeting, Differentiation and Function of Hematopoietic Cell Surfaces, Keystone, CO.
2. June, 1981 *Cytoskeletal Structures*, Cold Spring Harbor Symposium, Organization of the Cytoplasm, Cold Spring Harbor, NY.
3. November, 1982 *Human Erythrocyte Band 4.9.*, 22nd Annual Meeting, American Society for Cell Biology, Baltimore, MD.
4. December, 1982 *Human Erythrocyte Band 4.9*, Department of Hematology, St. Elizabeth's Hospital, Boston, MA.
5. January, 1983 *Human Erythrocyte Band 4.9*, Department of Cell and Developmental Biology, Harvard University, Boston, MA.
6. April, 1983 *Human Erythrocyte Band 4.9*, Boston Blood Club, Harvard Medical School, Boston, MA.
7. June, 1983 *Band 4.9, an Actin-Bundling Protein*, Department of Hematology/Oncology, Children's Hospital, Boston MA.
8. June, 1983 *Band 4.9, an Actin-Bundling Protein*, Department of Biochemistry and Molecular Biology, Harvard University, Boston, MA.
9. August, 1983 *Band 4.9, an Actin-Bundling Protein*, Red Cell Gordon Conference, Portsmouth, NH.
10. December, 1983 *Band 4.9, an Actin-Bundling Protein*, 23rd Annual Meeting, American Society for Cell Biology, San Antonio, TX.

11. January, 1984 *Human Erythrocyte Cytoskeletal Organization -- Normal and Pathologic States*, Hematology Department, Children's Hospital of Philadelphia, Philadelphia, PA.
12. February, 1984 *The Human Erythrocyte Cytoskeleton*, Cell Motility Club, Department of Anatomy, University of Pennsylvania, School of Medicine, Philadelphia, PA.
13. May, 1985 *The Relationship Between the Structure and Function of the Human Erythrocyte Membrane*, Department of Pathology and Laboratory Medicine, University of Pennsylvania, School of Medicine, Philadelphia, PA.
14. November, 1987 *Differential Expression of Activation Antigens on Peripheral Blood Lymphocytes in Renal Allograft Recipients During Episodes of Rejection and Infection*, 8th Annual Philadelphia Regional Immunology Conference, Philadelphia, PA.
15. June, 1988 *Differential Expression of Activation Antigens on Peripheral Blood Lymphocytes in Renal Allograft Recipients During Episodes of Rejection and Infection*, 7th Annual Meeting, American Society of Transplant Physicians, Chicago, IL.
16. June, 1988 *Distinguishing Rejection from Viral Infection in Renal Allograft Recipients Using Flow Cytometry*, Annual Meeting, Academy of Clinical Laboratory Physicians and Scientists, Cincinnati, OH.
17. June, 1988 *Monitoring Patients with Pancreas Allografts*, Annual Meeting, Academy of Clinical Laboratory Physicians and Scientists, Cincinnati, Ohio.
18. February, 1991 *Molecular Dissection of Human Red Cell Membrane Antigens*, Department of Pathology, SUNY Stony Brook School of Medicine, Stony Brook, New York.
19. April, 1991 *Molecular Dissection of Human Red Cell Membrane Antigens*, Department of Pathology, University of Chicago, Chicago, Ill.
20. April, 1991 *Molecular Dissection of Human Red Cell Membrane Antigens*, Department of Laboratory Medicine, Yale School of Medicine, New Haven, Conn.
21. May, 1991 *Molecular Dissection of Human Red Cell Membrane Antigens*, Lindsley F. Kimball Research Institute of the New York Blood Center, New York, NY.
22. November, 1992 *Production of Human Red Cell Antibodies in Bacteria by Repertoire Cloning. Plenary Session*, 45th Annual Meeting of the American Association of Blood Banks, San Francisco, CA.
23. April, 1993 *In Vitro Production of Anti-Red Cell Antibodies*, Pennsylvania Society for Medical Technologists, Annual Meeting, Valley Forge, PA
24. October, 1993 *Expression and Characterization of Recombinant Anti-Rh(D) Antibodies on Filamentous Phage: A Model System for Isolating Human Red Cell Antibodies by Repertoire Cloning*, The Center for Blood Research, Boston, MA.

25. October, 1993 *Isolation of Recombinant Human Anti-Rh(D) Antibodies From Libraries Expressed on M13 Phage*, 46th Annual Meeting of the American Association of Blood Banks, Miami, FL.
26. November, 1993 *Blood Component Therapy*, CME seminar, Doylestown Hospital, Doylestown, PA.
27. July, 1994 *Isolation of Human Anti-Red Blood Cell Antibodies by Repertoire Cloning*, International Conference on Immunoglobulin Gene Expression in Development and Disease, The New York Academy of Sciences, Montreal, Quebec, Canada.
28. January, 1995 *Production of Recombinant Anti-Red Blood Cell Antibodies on Filamentous Bacteriophage*, Visiting Professor, University of Tennessee, Memphis, Tennessee.
29. September, 1996 *Molecular Characterization of the Human Anti-Rh Immune Response Using Fab-Phage Display*. Grand Rounds, Department of Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA
30. October, 1996 *A Plethora of Human Monoclonal Anti-Rh Antibodies Isolated Using Phage Display and Magnetically-Activated Cell Sorting*, Plenary Session, 49th Annual Meeting of the American Association of Blood Banks, Orlando, FL.
31. October, 1996 *Molecular Characterization of the Human Anti-Rh Immune Response Using Fab-Phage Display*, Ortho Diagnostics Systems, Inc., Raritan, NJ.
32. November, 1996 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, Wistar Institute, Philadelphia, PA.
33. November, 1996 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 1996 Cold Spring Harbor Laboratory Course on Monoclonal Antibodies from Combinatorial Libraries, Cold Spring Harbor, NY.
34. November, 1996 *Molecular Characterization of the Human Anti-Rh Immune Response Using Fab-Phage Display*, Lindsley F. Kimball Research Institute of the New York Blood Center, New York, NY.
35. December, 1996 *Highly-Efficient Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, Seventh IBC Conference on Antibody Engineering, San Diego, CA.
36. December, 1996 *Efficient Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display: Applications in Transfusion Medicine*, Immunology Group, Smith Kline Beecham, Inc., King of Prussia, PA.
37. January, 1997 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display: Applications in Transfusion Medicine*, Scripps' Research Institute, La Jolla, CA.
38. January, 1997 *Molecular Characterization of the Human anti-Rh Immune Response Using Fab/Phage Display*, Immunology Colloquium, Immunology Graduate Group, University of Pennsylvania.

39. May, 1997 *Monoclonal Bacteriophage Antibodies*, 1997 Illinois Association of Blood Banks Quad State blood bank meeting, Chicago, IL.
40. May, 1997 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display: Applications in Immunohematology*, Department of Immunology and Microbiology, Allegheny University of the Health Sciences, Philadelphia, PA.
41. September, 1997 *Recombinant Phage-Displayed Human Anti-Red Blood Cell Antibodies and Blood Banking: A New Way to Type Blood*, Delaware Valley Blood Bank Club, Penn-Jersey Red Cross, Philadelphia, PA.
42. September, 1997 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display: Applications in Transfusion Medicine*, Pathology Department Grand Rounds, New York Hospital/Cornell Medical Center, New York, NY.
43. October, 1997 *New Approaches to Monoclonal Antibody Production*, Annual Seminar, 50th Annual Meeting of the American Association of Blood Banks, Denver, CO.
44. November, 1997 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 1997 Cold Spring Harbor Laboratory Course on Phage Display of Combinatorial Antibody Libraries, Cold Spring Harbor, NY
45. December, 1997 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display: Applications in Immunohematology*, Prolifaron, Inc., La Jolla, CA.
46. December, 1997 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display: Applications in Immunohematology*, Gamma Biologicals, Inc., Houston, TX.
47. February, 1998 *A New Approach for Human Monoclonal Antibody Production in Transfusion Medicine: Bacteriophage-Displayed Antibodies as Reagents for Blood Typing and Dissecting Rh Antigen Epitope Topology*, Department of Pathology, UCLA School of Medicine, Los Angeles, CA.
48. April, 1998 *Bacteriophage-Displayed Antibodies as Novel Reagents for Blood Typing and Understanding the Development of Human Immune Responses*, Laboratory Medicine Divisional Conference, Department of Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA.
49. April, 1998 *Molecular Characterization of the Human Anti-Rh Immune Response Using Fab/Phage Display*, Immunology Seminar Series, Mt. Sinai School of Medicine, New York, NY.
50. April, 1998 *New Insights into the Immunobiology of the Rh Antigen as Revealed by Phage Display Technology*, NHLBI, NIH, Bethesda, MD.
51. May, 1998 *A New Approach for Human Monoclonal Antibody Production: Bacteriophage-Displayed Antibodies as Reagents for Blood Typing and Dissecting Rh Antigen Epitope Topology*, 1998 Reference Laboratory Conference, American Red Cross, Washington, D.C.

52. June, 1998 *Molecular Characterization of the Human Anti-Rh Immune Response Using Fab/Phage Display*, Dyax Corporation, Cambridge, MA.
53. June, 1998 *The Dwindling Supply of Human Antisera for Blood Group Typing: A Solution Using Phage Display Technology*, Annual Meeting of the Academy of Clinical Laboratory Physicians and Scientists, Boston, MA.
54. August, 1998 *Molecular Characterization of the Human Red Cell anti-Rh Immune Response Using Fab/phage Display*, Abgenix, Inc., Fremont, CA.
55. October, 1998 *New Insights into the Immunobiology of the Human Rh Antigen as Revealed by Phage Display Technology*, Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, MA.
56. November, 1998 *Epitope Migration of Anti-D Antibodies*, 51st Annual Meeting of the American Association of Blood Banks, Philadelphia, PA.
57. November, 1998 *Isolation of Human IgG Platelet Autoantibodies Using Phage Display*, Plenary Session, 51st Annual Meeting of the American Association of Blood Banks, Philadelphia, PA.
58. November, 1998 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 1998 Cold Spring Harbor Laboratory Course on Phage Display of Combinatorial Antibody Libraries, Cold Spring Harbor, NY.
59. December, 1998 *Epitope Migration: Anti-Rh(D) Antibodies as a Model for Human Immunogenicity*, 40th Annual Meeting of the American Society for Hematology, Miami, FL.
60. January, 1999 *New Insights Into Human Monoclonal Anti-Rh and Anti-Platelet Antibodies as Revealed by Phage Display*, Hematology-Oncology Section Research Conference, Department of Medicine, University of Pennsylvania Medical Center.
61. January, 1999 *Characterization of Human Monoclonal Anti-RBC and Anti-Platelet Antibodies Using Phage Display*, Hematology Grand Rounds, Mt. Sinai School of Medicine, New York, NY.
62. February, 1999 *New Insights Into Human Monoclonal Anti-Rh and Anti-Platelet Antibodies as Revealed by Phage Display*. Laboratory Medicine Divisional Conference, Department of Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA.
63. March, 1999 *Use of Phage Display Technology for the Development of Blood Group Typing Reagents*, Cambridge Healthtech Institute's Phage Display -- Novel Therapeutics and Diagnostics: Applications in Product Development, Cambridge, MA.
64. April, 1999 *Dissecting Human Auto- and Alloimmune Responses to RBCs and Platelets Using Phage Display Technology*, Lindsley F. Kimball Research Institute of the New York Blood Center, New York, NY.
65. May, 1999 *Phage Display Technology and its Applications in the Field of Immunohematology and ITP*, 1999 International Society of Blood Transfusion, Jerusalem, Israel.

66. June, 1999 *Recombinant Approaches for Developing Diagnostic Reagents in Transfusion Medicine*, Annual Meeting of the Academy of Clinical Laboratory Physicians and Scientists, Birmingham, AL.
67. September, 1999 *Use of Repertoire Cloning and Antibody Engineering in the Design of Therapeutics* NIH/AABB-Sponsored Scientific Think Tank on "Setting the Research Agenda for Immunobiology in Transfusion Medicine," Bethesda, MD.
68. October, 1999 *Application of Molecular Biology to Immunoglobulin Engineering*, Molecular Biology in Blood Transfusion, 24th International Symposium, The Netherlands.
69. November, 1999 *Dissecting Human Auto- and Alloimmune Responses to RBCs and Platelets Using Phage Display Technology*, The Second Leonard Jarett MD Honorary Research Symposium, University of Pennsylvania School of Medicine.
70. November, 1999 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 1999 Cold Spring Harbor Laboratory Course on Phage Display of Combinatorial Antibody Libraries, Cold Spring Harbor, NY.
71. November, 1999 *Production of Large Repertoires of Macaque mAbs to Human RBCs Using Phage Display*, 52nd Annual Meeting of the American Association of Blood Banks, San Francisco, CA.
72. November, 1999 *Understanding Immunogenicity on a Molecular Level: New Insights Revealed by the Rh(D) Immune Response*, 52nd Annual Meeting of the American Association of Blood Banks, San Francisco, CA.
73. November, 1999 *Mechanism of Rh immune globulin prophylaxis revisited*, 52nd Annual Meeting of the American Association of Blood Banks, San Francisco, CA.
74. May, 2000 *Appropriate Use of Blood Products*, CME seminar, Phoenixville Hospital, Phoenixville, PA.
75. June, 2000 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display*, NCI-sponsored workshop, Molecular Diversity-Based Discovery of Tumor-Specific Diagnostic Markers and Probes, Bethesda, MD.
76. September, 2000 *Phage Display and anti-Rh(D) Repertoire*, Sixth Symposium on Platelet, Granulocyte and Red Cell Immunobiology, Amsterdam, Netherlands.
77. October, 2000 *Epitope Migration of Anti-Rh(D) Antibodies and the Concept of Red Cell Antigen Immunogenicity*, Blood Research Institute, Milwaukee, Wisconsin.
78. November, 2000 *What's a Clinically Significant Antibody?* 53rd Annual Meeting of the American Association of Blood Banks, Washington, D.C.
79. November, 2000 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 2000 Cold Spring Harbor Laboratory Course on Phage Display of Combinatorial Antibody Libraries, Cold Spring Harbor, NY.

80. May, 2001 *Staph Protein A Columns*, 22nd Annual Meeting of the American Society for Apheresis, Niagara Falls, NY.
81. July, 2001 *Recombinant Monoclonal Antibody Technology*, 4th International Workshop on Monoclonal Antibodies Against Human Red Blood Cells and Related Antigens, Paris, France, (*Plenary Lecture*)
82. July, 2001 *Structural Analysis of Monoclonal Antibodies to Blood Group Antigens*, Coordinator's Report, 4th International Workshop on Monoclonal Antibodies Against Human Red Blood Cells and Related Antigens, Paris, France.
83. October, 2001 *Dissecting Human Auto- and Alloimmune Responses to RBCs and Platelets Using Phage Display Technology*, Microbiology and Immunology Seminar Series, MCP Hahnemann Univ. School of Medicine, Philadelphia, PA.
84. October, 2001 *What's a Clinically Significant Antibody?* 54th Annual Meeting of the American Association of Blood Banks, San Antonio, TX.
85. October, 2001 *Antibody Phage Display: Implications for Reagent Production and Treatment of Antibody-Mediated Disease*, Workshop on Application of Molecular Biology to Immunohematology, 54th Annual Meeting of the American Association of Blood Banks, San Antonio, TX.
86. November, 2001 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 2001 Cold Spring Harbor Laboratory Course on Phage Display of Combinatorial Antibody Libraries, Cold Spring Harbor, NY.
87. December, 2001 *Understanding Immunogenicity on a Molecular Level: New Insights Revealed by the Rh Immune Response*, Scientific Committee on Transfusion Medicine: The Immune Response to Transfusion, 43rd Annual Meeting of the American Society for Hematology, Orlando, FL.
88. April, 2002 *Thrombotic Thrombocytopenic Purpura (TTP): Exciting recent findings which have advanced our understanding of disease pathogenesis and treatment by plasmapheresis*, Pennsylvania Society for Clinical Laboratory Science Annual Meeting, King of Prussia, PA.
89. April, 2002 *Dissecting Human Auto- and Alloimmune Responses to RBCs and Platelets Using Phage Display Technology: Diagnostic and Therapeutic Implications*, Department of Biologics Research, Merck Research Laboratories, Rahway, NJ.
90. May, 2002 *Dissecting Human Auto- and Alloimmune Responses to RBCs and Platelets Using Phage Display Technology*, Transfusion Medicine Grand Rounds, Joint Harvard Program in Transfusion Medicine, Harvard Medical School, Boston, MA.
91. May, 2002 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies to Red Cells and Platelets Using Phage Display and Magnetically-Activated Cell Sorting*, New England Biolabs, Beverly, MA.

92. September, 2002 *Developing New Diagnostic and Therapeutic Tools for Immune-Mediated Diseases Using Antibody Engineering*, Duhring Lecture, Division of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA.
93. September, 2002 *The Use of Phage Display to Develop Rational Therapies for the Treatment of Autoimmune Platelet Disorders (ITP)*, Conference on Display Technologies Accelerating Drug Discovery, Strategic Research Institute, Long Branch, NJ.
94. October, 2002 *Genetic Analyses of Human Immune Responses to Red Cells and Platelets*, Rheumatology Division Grand Rounds, UCSD, San Diego, CA.
95. October, 2002 *Autoimmune Thrombocytopenic Purpura (ITP): Current Treatment Options and Those on the Horizon*, Department of Medicine Grand Rounds, UCSD, San Diego, CA.
96. October, 2002 *Antibody Phage Display: Implications for Reagent Production and Treatment of Antibody-Mediated Disease*, Workshop on Application of Molecular Biology to Immunohematology, 55th Annual Meeting of the American Association of Blood Banks, Orlando, FL.
97. November, 2002 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 2002 Cold Spring Harbor Laboratory Course on Phage Display of Combinatorial Antibody Libraries, Cold Spring Harbor, NY.
98. December, 2002 *Cloning of Anti-Platelet Autoantibodies*, ITP Workshop, 44th Annual Meeting of the American Society for Hematology, Philadelphia, PA.
99. March, 2003 *Phage Display Technology*, BioRexis, Inc., King of Prussia, PA.
100. April, 2003 *Use of Phage Display Technology for Developing Diagnostic and Therapeutic Reagents*, Laboratory Medicine Residents' Noon Seminar, Department of Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA.
101. May, 2003 *Creating Diagnostic and Therapeutic Molecules Using Phage Display*, Hematology/Oncology Research Seminar Series, Children's Hospital of Philadelphia, Philadelphia, PA.
102. June, 2003 *Antibody Phage Display for Reagent and Therapeutic Antibody Production*, Current Topics in Blood Banking Conference, University of Michigan, Ann Arbor, MI.
103. June, 2003 *Etiology and Management of ITP*, Current Topics in Blood Banking Conference, University of Michigan, Ann Arbor, MI.
104. June, 2003 *Antibody Phage Display for Reagent and Therapeutic Antibody Production*, Targeted Molecules, Inc., San Diego, CA
105. September, 2003 *Blood Transfusion Risks*, Department of Urology Grand Rounds, University of Pennsylvania Medical Center, Philadelphia, PA.

106. September, 2003 *Developing New Diagnostic and Therapeutic Tools for Immune-Mediated Diseases Using Antibody Engineering*, Renal Research Conference, University of Pennsylvania School of Medicine, Philadelphia, PA.
107. October, 2003 *Phage Display Technology for the Development of Novel Diagnostic and Therapeutic Agents*, 12th Annual Meeting of the Great Lakes International Imaging and Flow Cytometry Association, Milwaukee, WI.
108. November, 2003 *Diagnostic and Therapeutic Applications of Phage Display Technology*, Session on Emerging Technologies and Therapies in Transfusion Medicine, 56th Annual Meeting of the American Association of Blood Banks, San Diego, CA.
109. November, 2003 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 2003 Cold Spring Harbor Laboratory Course on Phage Display of Combinatorial Antibody Libraries, Cold Spring Harbor, NY.
110. December, 2003 *Characterization of an ITP Patient-Derived Anti- $\alpha_2\beta_3$ Monoclonal Antibody that Inhibits Platelet Aggregation*, 45th Annual Meeting of the American Society for Hematology, San Diego, CA.
111. April, 2004 *Transfusion Medicine Overview*. Weekly Conference, Division of Vascular Surgery, Department of Surgery, University of Pennsylvania Medical Center.
112. April, 2004 *Clinical, Educational, and Research Activities of Division of Transfusion Medicine*, Department of Pathology & Laboratory Medicine Academic Retreat, College of American Physicians, Philadelphia, PA.
113. May, 2004 *Therapeutic Apheresis/Extra-Corporeal Selective Extraction Techniques*. World Apheresis Association/American Association of Apheresis Joint Meeting, Miami, FL.
114. October, 2004 *Phage Display Tools for Automated Blood Typing*. Plenary Session, 57th Annual Meeting of the American Association of Blood Banks, Baltimore, MD.
115. October, 2004 *Diagnostic and Therapeutic Applications of Phage Display Technology*, Session on Emerging Technologies and Therapies in Transfusion Medicine, 57th Annual Meeting of the American Association of Blood Banks, Baltimore, MD.
116. November, 2004 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 2004 Cold Spring Harbor Laboratory Course on Phage Display of Peptides and Proteins, Cold Spring Harbor, NY.
117. December, 2004 *Review of Different Kinds of Blood Components and the Indications and Risks of Their Use*, Grand Rounds CME Program, The Chester County Hospital, West Chester, PA.
118. January, 2005 *ITP and the Mechanism of Action of Staphylococcal Protein A Plasmapheresis*, Allergy & Immunology Divisional Conference, University of Pennsylvania School of Medicine, Philadelphia, PA.

119. May, 2005 *Diagnostic and Therapeutic Applications of Phage Display Technology*, The 8th Leonard Jarett MD Honorary Research Symposium, University of Pennsylvania School of Medicine.
120. June, 2005 *Transfusion Medicine Overview*, Weekly Teaching Conference, Division of Maternal-Fetal Medicine, HUP.
121. June, 2005 *Use of Phage Display to Study Human Autoimmune Disease: ITP as a Paradigm*, “Pemphigus 2005, Progress and Future Directions”, an international meeting sponsored jointly by the International Pemphigus Foundation, The American Autoimmune Related Diseases Association, and the NIH NIAMS, Bethesda. MD.
122. July, 2005 *Graduate Pathology Education: What are we missing for a competent trainee product for the future?* Annual Summer Meeting, Association of Pathology Chairs, Mont-Tremblant Quebec, Canada.
123. October, 2005 *Overview of Antibody and Peptide Phage Display*. Program on Applications of Phage Display to Blood Transfusion Medicine, 58th Annual Meeting of the American Association of Blood Banks, Seattle, WA.
124. October, 2005 *Cutting-Edge Technologies in Apheresis*. Board of Penn Medicine. Fall meeting, Philadelphia, PA.
125. October, 2005 *Transfusion Medicine Overview*. Grand Rounds, Department of Anesthesiology and Critical Care, Hospital of the University of Pennsylvania, Philadelphia, PA.
126. October, 2005 *Dissecting the Immunobiology of ITP*. Annual UPenn CME Course entitled, “New Insights into Coagulation”, Philadelphia, PA.
127. November, 2005 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 2005 Cold Spring Harbor Laboratory Course on Phage Display of Peptides and Proteins, Cold Spring Harbor, NY.
128. February, 2006 *Transfusion Medicine Overview*. Grand Rounds, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA.
129. May, 2006 *Cloning and Characterization of Human Monoclonal Autoantibodies in TTP*. 27th Annual Meeting of the American Society for Apheresis, Las Vegas, NV.
130. September, 2006 *Overcoming limitations in current pre-transfusion compatibility testing methods using phage display technology*. FDA Workshop on Molecular Methods in Immunohematology, Bethesda, MD.
131. November, 2006 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 2006 Cold Spring Harbor Laboratory Course on Phage Display of Peptides and Proteins, Cold Spring Harbor, NY.
132. December, 2006 *Phage Display Tools for Diagnosis and Therapy*. Sanofi-Aventis, Inc., Bridgewater, New Jersey.

133. December, 2006 *Inhibitory ADAMTS13 Monoclonal Autoantibodies Cloned from TTP Patients Show Restricted Gene Usage, Inhibit Murine ADAMTS13, and are Blocked by Rabbit Anti-Idiotypic Antibodies*, 48th Annual Meeting of the American Society for Hematology, Orlando, FL.
134. January, 2007 *Phage Display Tools for Inhibiting Platelet Activation in TTP and Other Thrombotic Disorders*, Human Translational Immunology Speaker Series, University of Pennsylvania, Philadelphia, PA.
135. March, 2007 *Immunobiology of Immune Thrombocytopenias*, Grantees' Meeting for SCCOR in Hemostasis and Thrombotic Disease, NHLBI, NIH, Bethesda, MD.
136. April, 2007 *Phage Display Tools for Inhibiting Platelet Activation in TTP*, Grand Rounds, Department of Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA.
137. June, 2007 *Blood Bank and Transfusion Medicine Overview*, Grand Rounds, Department of Neurosurgery, Hospital of the University of Pennsylvania, Philadelphia, PA.
138. July, 2007 *Blood Bank and Transfusion Medicine Overview*, Grand Rounds, Department of Emergency Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA.
139. October, 2007 *Thrombotic Thrombocytopenic Purpura*, Cytopenias in 2007: Emphasis on ITP, San Diego, CA.
140. November, 2007 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 2007 Cold Spring Harbor Laboratory Course on Phage Display of Peptides and Proteins, Cold Spring Harbor, NY.
141. December, 2007 *Characterizing the Humoral Autoimmune Response in a Thrombotic Disorder: TTP as a Paradigm*, Scientific Subcommittee Meeting Education Session, 49th Annual Meeting of the American Society for Hematology, Atlanta, GA.
142. January, 2008 *Effective Use of Clinical Laboratory Tests*, Group for Research in Pathology Education, Annual Meeting, Philadelphia, PA.
143. April, 2008 *How Diversity in Humoral Immune Response is Generated*, Immunohematology Reference Laboratory National Conference, American Red Cross, Scottsdale, AR.
144. April, 2008 *Clinical Aspects of Autoimmune Hemolytic Anemia*, Immunohematology Reference Laboratory National Conference, American Red Cross, Scottsdale, AR.
145. April, 2008 *Phage Display-Based High-Throughput Screening for Diagnostic and Therapeutic Antibody Discovery*, Department of Pathology & Laboratory Medicine Research Retreat, College of American Physicians, Philadelphia, PA.
146. May, 2008 *Immunobiology of Immune Thrombocytopenias*, Grantees' Meeting for SCCOR in Hemostasis and Thrombotic Disease, NHLBI, NIH, Bethesda, MD.

147. June, 2008 *Phage Display-Based High-Throughput Screening for Diagnostic and Therapeutic Antibody Discovery*. Academy of Clinical Laboratory Physicians and Scientists, Annual Meeting, Philadelphia, PA.
148. September, 2008 *Transfusion Medicine Overview*, Grand Rounds, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA.
149. October, 2008 *A Interesting Prenatal Workup*, Medical Advisory Committee Meeting, American Red Cross, Penn-Jersey Region, Philadelphia.
150. October, 2008 *Research Opportunities for Transfusion Medicine Residents and Fellows*, Session on Fellowship Training in Transfusion Medicine, 60th Annual Meeting of the American Association of Blood Banks, Montreal, Canada.
151. November, 2008 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 2008 Cold Spring Harbor Laboratory Course on Phage Display of Peptides and Proteins, Cold Spring Harbor, NY.
152. February, 2009 *Transfusion Reactions*, Grand Rounds, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA.
153. February, 2009 *What Role Do B Cells Play in Autoimmunity?* Haematological Aspects of Autoimmune Diseases, European School of Haematology, Mandelieu, France.
154. March, 2009 *Building a New Blood Bank*, Medical Advisory Committee Meeting, American Red Cross, Penn-Jersey Region, Philadelphia.
155. April, 2009 *Transfusion-Associated Acute Lung Injury*, Grand View Hospital, Sellersville, PA.
156. April, 2009 *Use of Phage Display to Develop Therapeutic Antibodies for the Treatment of TTP, a Potentially Fatal Autoimmune Thrombotic Disorder* 11th Annual Phage Display of Antibodies and Peptides, PEGS Protein Engineering Summit, Boston, MA.
157. June, 2009 *Immunobiology of Immune Thrombocytopenias*, Grantees' Meeting for SCCOR in Hemostatic and Thrombotic Disease, NHLBI, NIH, Bethesda, MD.
158. June, 2009 *State of the Art on Antibody-Mediated Autoimmunity*, Keynote Lecture, International Pemphigus Meeting, Berne, Switzerland.
159. September, 2009 *Transfusion-Related Acute Lung Injury*, Cytopenias and Hemostasis in 2009, Orlando, FL.
160. November, 2009 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 2009 Cold Spring Harbor Laboratory Course on Phage Display of Peptides and Proteins, Cold Spring Harbor, NY.
161. December, 2009 *Transfusion Medicine Overview: Blood Components, Indications, and Risks*, Medical Grand Rounds, Wilmington VA Medical Center, Wilmington, DE.

162. January, 2010 *Phage Display*, Molecular and Cellular Biology Seminar Series, School of Graduate Studies, SUNY Downstate Medical Center, Brooklyn, NY.
163. April, 2010 *TTP: New Developments in Understanding Its Pathophysiology and in Designing More Effective Therapies*, New Frontiers in Transfusion Medicine, Brown University, Providence, RI.
164. April, 2010 *Phage Display*, Program in Targeted Therapeutics “Work in Progress” seminar series, Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA.
165. April, 2010 *Phage Display*, Rheumatology Division, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA.
166. June, 2010 *Immunobiology of Immune Thrombocytopenias*, Grantees’ Meeting for SCCOR in Hemostatic and Thrombotic Disease, NHLBI, NIH, Bethesda, MD.
167. October, 2010 *Cellular and Molecular (Phage Display) Methods for Producing Monoclonal Antibodies*, 2010 United States Anti-Doping Agency Symposium, Leesburg, VA.
168. October, 2010 *Use of Mouse Models to Study the Role ADAMTS13 Plays in Thrombotic Disorders*, Program on Mouse Models in Transfusion Medicine: Hematological Disorders, 2010 Annual Meeting of the AABB, Baltimore, MD.
169. November, 2010 *The Expanding Scope of Transfusion Medicine*, Western and Midwestern APC/PDAS Annual Meeting, Kamuela, Hawaii.
170. November, 2010 *Use of Phage Display Technologies for Developing Diagnostic Reagents*. Western and Midwestern APC/PDAS Annual Meeting, Kamuela, Hawaii.
171. November, 2010 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 2010 Cold Spring Harbor Laboratory Course on Phage Display of Peptides and Proteins, Cold Spring Harbor, NY.
172. January, 2011 *Use of Phage Display for Developing Blood Bank Reagents and for Understanding Autoimmune Disorders Relevant to Transfusion Medicine*, Department of Transfusion Medicine Grand Rounds, NIH Clinical Research Center, Bethesda, MD.
173. February, 2011 *Phage Display Technology: Application to the Study of Human Autoimmune Disorders*, Grand Rounds, Department of Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA.
174. June, 2011 *The Evolving Roles of Apheresis and Transfusion Medicine in Cellular Therapies*, Plenary Session, 2011 Annual Meeting of the American Society for Apheresis, Scottsdale, AR.
175. June, 2011 *The Expanding Role of Pathologists in Personalized Medicine and Therapeutics*. Eleventh Annual Peter S. Amenta, M.D., Ph.D. Lectureship in Pathology, Annual Graduation Ceremony, Department of Pathology & Laboratory Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ.

176. October, 2011 *"Hit and Run" Gene/Cell Therapy Protocol for HIV Using Zinc Finger Endonucleases*, Scientific Hot Topics in Transfusion Medicine, Annual Meeting of the American Association of Blood Banks, San Diego, CA.
177. November 2011 *The Evolving Roles of Apheresis and Transfusion Medicine in Cellular Therapies*, Fenwal, Inc., Lake Zurich, IL.
178. November, 2011 *The Expanding Role of Transfusion Medicine in Personalized Medicine and Therapeutics*, Laboratory Medicine Grand Rounds, Department of Laboratory Medicine, University of Washington School of Medicine. Seattle, WA.
179. April, 2012 *Developing Novel Therapies for TTP*, Plenary Session, 2012 Annual Meeting of the American Society for Apheresis, Atlanta, Georgia.
180. May, 2012 *The Expanding Role of Transfusion Medicine in Personalized Medicine and Therapeutics*, ASCLS-PA State Spring Meeting, University of the Sciences, Philadelphia, PA.
181. October, 2012 *Transfusion Medicine Physicians Career Development and Networking Dinner*, Featured Speaker, 2012 Annual Meeting of the American Association of Blood Banks, Boston, MA.
182. October, 2012 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 2012 Cold Spring Harbor Laboratory Course on Phage Display of Peptides and Proteins, Cold Spring Harbor, NY.
183. February, 2013 *Immunobiology of Thrombotic Thrombocytopenic Purpura (TTP)*, Grand Rounds, Division of Laboratory and Genomic Medicine, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO.
184. October, 2013 *The Evolving Roles of Transfusion Medicine and Cellular Engineering for Hematologic Disorders*, Inaugural Annual Blood Center Symposium, The Penn-CHOP Blood Center for Patient Care & Discovery
185. October, 2013 *Clinical Vaccine Production Facility at the Hospital of the University of Pennsylvania: Bench to Bedside in an Existing Hospital*, 7th Annual Conference, Academic Medical and Health Science Centers 2013, Orlando, FL.
186. November, 2013 *Phage Display Approaches for Devising New Translational Affinity Moieties for Drug Targeting*, Center for Targeted Therapeutics & Translational Nanomedicine, 2013 Annual Symposium, Philadelphia, PA.
187. November, 2013 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 2013 Cold Spring Harbor Laboratory Course on Phage Display of Peptides and Proteins, Cold Spring Harbor, NY.
188. December, 2013 *Immunobiology of Thrombotic Thrombocytopenic Purpura (TTP)*, Weekly Seminar Series, Penn-CHOP Blood Center for Patient Care & Discovery.

189. January, 2014 *Immunobiology of Thrombotic Thrombocytopenic Purpura (TTP)*, Division of Laboratory Medicine Seminar Series, Department of Pathology & Cell Biology, Columbia University College of Physicians and Surgeons, New York, NY.
190. February, 2014 *Update on Hematopoietic Stem Cell Transplantation*, 2nd Annual UC San Diego Essentials & Advances in Apheresis Therapies, San Diego, CA.
191. February, 2014 *The Evolving Role of Cell Therapies*, 2nd Annual UC San Diego Essentials & Advances in Apheresis Therapies, San Diego, CA.
192. February, 2014 *Cell Harvest, Bone Marrow Transplantation, Advanced Cell Uses, Graft-v-Host Disease*, Breakfast with the Experts, 2nd Annual UC San Diego Essentials & Advances in Apheresis Therapies, San Diego, CA.
193. April, 2014 *Engineering Apheresis-Derived T Cells to Treat Cancer*, 2014 Annual Meeting of the American Society for Apheresis, San Francisco, CA.
194. August, 2014 *Medullary Thyroid Cancer and (Very) Personalized Medicine*, Scripps Research Institute, La Jolla, CA.
195. September, 2014 *Personalized Drugs of the Future: Apheresis Medicine-enhanced Gene and Cell Therapy*, International Society for Blood Purification and Therapeutic Apheresis Academy 2014 Joint Conference, National Harbor, MD.
196. September, 2014 *Phage Display, Metastatic Cancer, and (Very) Personalized Medicine*, New England Biolabs, Ipswich, MA.
197. October, 2014 *Facility Considerations: Video Presentation from U Penn*, Workshop on CAR T Cell Adoptive Therapies: Product Engineering to Clinical Outcomes, 2014 Annual Meeting of the AABB, Philadelphia, PA.
198. November, 2014 *Isolation of Cell Surface-Specific Human Monoclonal Antibodies Using Phage Display and Magnetically-Activated Cell Sorting*, 2014 Cold Spring Harbor Laboratory Course on Phage Display of Peptides and Proteins, Cold Spring Harbor, NY.
199. December, 2014 *Use of Phage Display to Characterize the Immunobiology of TTP, a potentially fatal clotting disorder*, The Donnelly Centre, University of Toronto, Toronto, Ontario.
200. April, 2015 *Transfusion Medicine: It's Better to Give than to Receive*, Internal Medicine 2015, American College of Physicians, Boston, MA.
201. September, 2015 *Characterization of Pathogenic Autoantibodies in a Potentially Fatal Autoimmune Disease: TTP as a Paradigm*, New Therapies for Pemphigus and their Underlying Science, Paris France.
202. November, 2015 *Human Phage Display Libraries, Cell Surface Panning, Translational Medicine Applications, and Llamas*, 2015 Cold Spring Harbor Laboratory Course on Antibody Engineering and Phage Display, Cold Spring Harbor, NY.

203. November, 2015 *Phage Display-Derived Antibodies for Personalized Chimeric Antigen Receptor T-Cell Therapy*, 2015 Cold Spring Harbor Laboratory Course on Antibody Engineering and Phage Display, Cold Spring Harbor, NY.
204. April, 2016 *Phage Display, Metastatic Cancer, and CART Therapy for Medullary Thyroid Cancer*, Pathology Grand Rounds, Virginia Commonwealth University, Richmond, VA.
205. July, 2016 *CART Therapy for Medullary Thyroid Cancer*, REACT Thyroid Cancer Foundation, Annual Meeting, Chicago, IL.
206. October, 2016 *Overview of Role of Apheresis in Cell Therapy Manufacturing*, Workshop 4: Leaving the Single-Center Orbit: New Horizons in Clinical Cell Therapy, International Society for Cell Therapy North American 2016 Regional Meeting, Memphis, TN.
207. October, 2016 *The Evolving Role of the Blood Bank/Transfusion Medicine Specialist in the Development and Administration of Novel Cell Therapies*, Workshop 6: Cell Therapy Professional Development, International Society for Cell Therapy North American 2016 Regional Meeting, Memphis, TN.
208. October, 2016 *cGMP Laboratory Basics*, 2016 Annual Meeting of the AABB, Orlando, FL.
209. November, 2016 *Translational Aspects of Antibody Phage Display*, 2016 Cold Spring Harbor Laboratory Course on Antibody Engineering, Phage Display & Immune Repertoire Analysis, Cold Spring Harbor, NY.
210. December, 2016 *Careers in Transfusion Medicine*, 2016 Meeting of the American Society for Hematology, San Diego, CA.
211. January, 2017 *Phage-Display Derived Tools for Glioblastoma Immunotherapy*, Grand Rounds, Department of Neurosurgery, Hospital of the University of Pennsylvania, Philadelphia, PA.
212. January, 2017 *Use of Chimeric Antigen Receptor T Cells (CAR-T) for Cancer Immunotherapy*, Grand Rounds, Department of Neurosurgery, SUNY Stony Brook, Stony Brook, NY.
213. January, 2017 *Pre-Procedural Use of FFP*, Clinical Controversies, Grand Rounds, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA.
214. March, 2017 *Phage Display-Derived Antibodies for Personalized Chimeric Antigen Receptor T-Cell Therapy*, Tri-Institutional Therapeutics Discovery Institute Antibody Discover Seminar, Memorial Sloan Kettering Cancer Center/The Rockefeller University/Weill Cornell Medicine, New York, NY.
215. May, 2017 *Use of Chimeric Antigen Receptor T-Cells (CAR-T) for Cancer Immunotherapy*, Department of Biomedical Engineering, University of Southern California, Los Angeles, CA.
216. May, 2017 *Phage Display-Derived Antibodies for Personalized Chimeric Antigen Receptor T-Cell Therapy*, Cancer Biology Program, The Scripps Research Institute, Jupiter, FL.

217. June, 2017 *Appropriate Transfusion of Red Blood Cells and Platelets – Lessons for the Oncologist*, 2017 Hematology for the Practicing Oncologist, 2017 Meeting of the American Society of Clinical Oncology, Chicago, IL.
218. October, 2017 *Cellular Therapy Development – Target Identification, Vector Design, and Manufacture*, Session on How to Make a Cellular Immunotherapy”, 2017 Meeting of the AABB, San Diego, CA.
219. October, 2017 *Translational Aspects of Antibody Phage Display*, 2017 Cold Spring Harbor Laboratory Course on Antibody Engineering, Phage Display & Immune Repertoire Analysis, Cold Spring Harbor, NY.
220. February, 2018 *CAR-T Technology*, KTH Royal Institute of Technology and AlbaNova University Center, Stockholm.
221. February, 2018 *CARLOS (Chimeric Antigen Receptor Lymphocytes with Oncolytic Specificity)*, KTH Royal Institute of Technology and AlbaNova University Center, Stockholm.
222. March, 2018 *CAR-T Cell Therapy*, 14th Annual Tucson Symposium 2018, Tucson, AZ.
223. April, 2018 *Engineering Apheresis-Derived Mononuclear Cells to Treat Cancer and Autoimmune Disease*, Francis S. Morrison, MD Memorial Lectureship, 2018 Meeting of the American Society for Apheresis, Chicago, IL.
224. April, 2018 *The Evolving Role of the Transfusion Medicine Specialist in the Development and Use of Novel Engineered Cell Therapies*, Grand Rounds, Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY.
225. June, 2018 *Engineering Apheresis-Derived Mononuclear Cells to Treat Cancer and Autoimmune Disease*, Pathology Grand Rounds, Brown University, Providence, RI.
226. November, 2018 *Personalized Therapy and Cellular Engineering*, Board of Women’s Visitors, Hospital of the University of Pennsylvania, Philadelphia, PA.
227. November, 2018 *New Approaches for the Development of Treatments for Thrombotic Thrombocytopenic Purpura*, The Ree Wynn Foundation, Mt. Laurel, NJ.
228. December, 2018 *Blood Doping in High-Performance Sport: a Chemical and Transfusion Medicine Arms Race*, 60th Annual Meeting of the American Society for Hematology, San Diego, CA.
229. December, 2018 *Phage Display-Derived Antibody Fragments for CAR-T Design*, Center for Cellular Immunotherapies Data Session, University of Pennsylvania, Philadelphia, PA.
230. March, 2019 *Overview & Update on CAR-T Cell Therapies*, Plenary Session, 2019 Essentials and Advances in Apheresis Therapies, San Diego, CA.
231. March, 2019 *Generating New Cell Therapies from Scratch*, 2019 Essentials and Advances in Apheresis Therapies, San Diego, CA.

232. March, 2019 *Updates in the Management of TTP*, 2019 Essentials and Advances in Apheresis Therapies, San Diego, CA.
233. March, 2019 *Chimeric Antigen Receptor T-Cells for Treating Cancer and Autoimmune Disease*, Keynote Speaker, Robert and Jean Adams Clinical Laboratory Sciences Symposium, Auburn University, Montgomery, AL.
234. March, 2019 *Chimeric Antigen Receptor T-Cells for Treating Cancer and Autoimmune Disease*, Grand Rounds, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL.
235. April, 2019 *New Roles for the Medical Laboratory Technologist in Cellular Therapies*, School of Medical Laboratory Science, Pennsylvania Hospital, Philadelphia, PA.
236. May, 2019 *Phage Display Tools for CAR-T Development*, Poseida Therapeutics, San Diego, CA.
237. May, 2019 *Use of Chimeric Antigen Receptor T-Cells (CAR-T) for Cancer Immunotherapy*, Scripps Research Institute, La Jolla, CA.
238. May, 2019 *Medullary Thyroid Cancer and (Very) Personalized Medicine*, Scripps Research Institute, La Jolla, CA.
239. May, 2019 *Current State of CAR-T Therapy*, Scientific Symposium, 2019 Meeting of the American Society for Apheresis, Portland, OR.
240. June, 2019 *Chimeric Antigen Receptor T-Cells for Treating Cancer and Autoimmune Disease*, Medical Grand Rounds, University of Massachusetts Medical School, Worcester, MA.
241. June, 2019 *Phage Display Tools for Chimeric Antigen Receptor-T Cell Development*, Grand Rounds, Department of Pathology, Stanford University School of Medicine, Stanford, CA.
242. September, 2019 *Collections for CAR-T Cells – How It All Started*, ISCT Regional Meeting, Madison, WI.
243. October, 2019 *Phage Display Tools for Chimeric Antigen Receptor-T Cell Development*, Glioblastoma Translational Center of Excellence data session, University of Pennsylvania, PA.
244. October, 2019 *Phage Display Tools for Chimeric Antigen Receptor-T Cell Development*, 2019 Cold Spring Harbor Laboratory Course on Antibody Engineering, Phage Display & Immune Repertoire Analysis, Cold Spring Harbor, NY.
245. October, 2019 *An Update on the Diagnosis and Treatment of Thrombotic Thrombocytopenic Purpura and a Glimpse into the Future*, 2019 Meeting of the AABB, San Antonio, TX.
246. October, 2019 *Beyond Conventional: Controversial Uses of Blood Components*, 2019 Meeting of the AABB, San Antonio, TX.
247. October, 2019 *Under the Hood of the CAR: Progress, Practical Considerations, and Product Quality Aspects of CAR-T Cell Development*, 2019 Meeting of the AABB, San Antonio, TX.

248. November, 2019 *Prospecting the Pipeline: Exploring the Implications of a Biopharmaceutical Pipeline Dominated by Personalized Treatments*, 15th Annual Personalized Medicine Conference, Harvard Medical School, Boston, MA.
249. November, 2019 *MNC Collection for CAR-T Cells: How It All Started*, 2019 ASFA Regional Meeting, Baltimore, MD.
250. December, 2019 *The Canine Immune Repertoire as a Source of Antibodies with Therapeutic Potential*, Center for Cellular Immunotherapies Data Session, University of Pennsylvania, Philadelphia, PA.
251. January, 2020 “*Unleashing*” *the Canine Immune Repertoire as a Source of Antibodies with Therapeutic Potential*, Canine Chimeric Antigen Receptor T-Cell Club, University of Pennsylvania, PA.
252. February, 2020 *Current State of CAR-T Therapy*, 2020 Mayo Clinic Transfusion Medicine and Cellular Therapy Symposium, Jacksonville, FL.
253. March, 2020 *CAR-T Therapy: Role of the Pathologist in this Cutting Edge Science and Patient Care*, United States & Canadian Academy of Pathology (USCAP) 109th Annual Meeting, Los Angeles, CA.
254. May, 2020 *Blood Doping in High-Performance Sport: A Chemical and Transfusion Medicine Arms Race*, New Jersey Association of Blood Bank Professionals (NJABBP), Woodbridge, NJ. (*postponed*)
255. May, 2020 *Current State of CAR-T Therapy*, New Jersey Association of Blood Bank Professionals (NJABBP), Woodbridge, NJ. (*postponed*)
256. June, 2020 “*Unleashing*” *the Canine Immune Repertoire as a Source of Antibodies for Dog and Human Immunotherapy*, Pathology & Laboratory Medicine Research-in-Progress Series, University of Pennsylvania, Philadelphia, PA (virtual).
257. July, 2020 *Phage Display Tools for Chimeric Antigen Receptor-T Cell Development*, International Society for the Advancement of Cytometry 2020, Philadelphia, PA (virtual)
258. August, 2020 *Collection for CAR-T Cells: How It All Started*, Division of Laboratory Medicine, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL. (virtual)
259. December, 2020 *Collection for Administration of Cell Therapies*, 2020 Center for Cellular Immunotherapies Clinical Retreat, University of Pennsylvania, PA (virtual)
260. February, 2021 *Phage Display Tools for Chimeric Antigen Receptor-T Cell Development*, Pathology Grand Rounds, Yale School of Medicine, New Haven, CT. (virtual)
261. March, 2021 *Expanding Target Binders from scFv to Camelid VHHs – Getting Over the Hump*, Center for Cellular Immunotherapies Data Session, University of Pennsylvania, Philadelphia, PA.

262. March, 2021 *The Canine Immune Repertoire as a Source of Canine Checkpoint Inhibitors*, Center for Cellular Immunotherapies Data Session, University of Pennsylvania, Philadelphia, PA.
263. May, 2021 *CAR-T Cells as Therapy for Medullary Thyroid Carcinoma*, 2021 International Thyroid Oncology Group Annual Meeting (virtual).
264. May, 2021 *Antibody Discovery for New CAR Constructs*, Cellicon Valley '21:, The Future of Cell and Gene Therapies (virtual).
265. May, 2021 *Project C.A.R.L.O.S.: Personalized Therapy for Medullary Thyroid Cancer*, Scripps Research Institute, La Jolla, CA and Jupiter, FL campuses (virtual)
266. October, 2021 *2021 Tibor Greenwalt Memorial Award and Lectureship: Project C.A.R.L.O.S*, 2021 Annual Meeting of the AABB (virtual).
267. October, 2021 *NBF Summit: What is the Greatest Challenge Facing the Blood and Biotherapies Industry*, 2021 Annual Meeting of the AABB (virtual).
268. October, 2021 *Phage Display Tools for Chimeric Antigen Receptor-T Cell Development (and other stuff)*, 2021 Cold Spring Harbor Laboratory Course on Antibody Engineering, Phage Display & Immune Repertoire Analysis, Cold Spring Harbor, NY.
269. February, 2022 *Unleashing the Canine Immune Repertoire to Help Our Best Friends*, Pathology & Laboratory Medicine Research-in-Progress Series, University of Pennsylvania, Philadelphia, PA (virtual).
270. March, 2022: *CAR T Therapy for Medullary Thyroid Cancer*, Grand Rounds, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Pennsylvania, Philadelphia, PA (virtual).
271. April, 2022 *Expanding Target Binders from scFv to Camelid VHHs: Getting Over the Hump, Part Deux*, Center for Cellular Immunotherapies Data Session, University of Pennsylvania, Philadelphia, PA.
272. May, 2022 *Current State of CAR-T Therapy*, New Jersey Association of Blood Bank Professionals (NJABBP), Woodbridge, NJ.
273. June, 2022 *CAR T-Cell Therapy for Thyroid Cancer: The Personal Story that Inspired the Science Focus on Medullary Thyroid Cancer*, Advances in Treatment and Cutting Edge Research, patient & caregiver program sponsored by Penn's Abramson Cancer Center and ThyCa: Thyroid Cancer Survivors' Association, Inc.
274. October, 2022 *Phage Display Tools for Chimeric Antigen Receptor-T Cell Development (and other stuff)*, 2022 Cold Spring Harbor Laboratory Course on Antibody Engineering, Phage Display & Immune Repertoire Analysis, Cold Spring Harbor, NY.
275. February, 2023 *Playing With Fire: Development of CAR-T Therapy in an Academic Medical Center*, Oklahoma Blood Institute (virtual).

276. April, 2023 *Novel Mesothelin Binders and Epitopes for CAR-T Design*, Center for Cellular Immunotherapies Data Session, University of Pennsylvania, Philadelphia, PA.
277. April, 2023 *Updates on VHH Single Domain Binders to BCMA*, Center for Cellular Immunotherapies Data Session, University of Pennsylvania, Philadelphia, PA.
278. May, 2023 *“Unleashing” the Canine Immune Repertoire as a Source of Antibodies with Therapeutic Potential – Part Deux*, Canine Chimeric Antigen Receptor T-Cell Club, University of Pennsylvania, PA.
279. May, 2023 *Project C.A.R.L.O.S.: Personalized Therapy for Medullary Thyroid Cancer*, Scripps Research Institute, La Jolla, CA and Jupiter, FL campuses (virtual).
280. September, 2023 *Promising Novel Cellular Therapy Approaches for Non-Malignant Hematologic Disorders*, 18th Annual Aster Lecture on Transfusion Medicine, Versiti Blood Research Institute/Medical Science Institute, Milwaukee, WI.
281. September, 2023 *ABCs of POC Manufacturing*, ISCT North America Regional Meeting, Houston, TX.
282. October, 2023 *State of the Science in Biotherapies Research*, 2023 AABB Annual Meeting, Nashville, TN.
283. October, 2023 *Phage Display Tools for Chimeric Antigen Receptor-T Cell Development (and other stuff)*, 2023 Cold Spring Harbor Laboratory Course on Antibody Engineering, Phage Display & Immune Repertoire Analysis, Cold Spring Harbor, NY.
284. January, 2024 *Innovation in the Development of Novel Cellular Therapies for Cancer, Autoimmune Disease and Other Maladies*, JPMorgan Chase Senior Leadership Conference on Innovation, Philadelphia, PA.
285. April, 2024 *Innovations in Novel Cellular Therapies for Cancer, Autoimmune Disease and Other Maladies*, Opening Symposium: CAR-T Mechanisms, 2024 Meeting of the American Society for Apheresis, Las Vegas, NV.
286. April, 2024 *Updates on Target Binders with a New Focus on LRRC15 (Leucine-Rich Repeat-Containing protein 15)*, Center for Cellular Immunotherapies Data Session, University of Pennsylvania, Philadelphia, PA.
287. May, 2024 *Innovations in Novel Cellular Therapies for Cancer, Autoimmune Disease and Other Maladies*, Pathology Grand Rounds, University of Kansas Medical Center, Kansas City, KS.
288. June, 2024 *Innovations in Novel Cellular Therapies for Cancer, Autoimmune Disease and Other Maladies*, Pathology Grand Rounds, Indiana University Medical Center, Indianapolis, IN.
289. June, 2024 *Innovations in Novel Cellular Therapies for Cancer, Autoimmune Disease and Other Maladies*, Transfusion, Apheresis, and Cellular Therapy Committee, College of American Pathologists (virtual).

290. October, 2024 *Phage Display Tools for Chimeric Antigen Receptor-T Cell Development (and other stuff)*, 2024 Cold Spring Harbor Laboratory Course on Antibody Engineering, Phage Display & Immune Repertoire Analysis, Cold Spring Harbor, NY.
291. November, 2024 *Developing Canine Immunotherapies to Fully Leverage Comparative Oncology and Inform Human Clinical Trials*, Advanced Therapies USA 2024, Philadelphia, PA.
292. November, 2024 *Project C.A.R.L.O.S.: CAR-T Therapy for Medullary Thyroid Cancer*, Pathology & Laboratory Medicine Grand Rounds Speaker Series, University of Pennsylvania, Philadelphia, PA.
293. January, 2025 *Transfusion Medicine Primer*, Penn Transplant Institute, Hospital of the University of Pennsylvania, Philadelphia, PA.
294. March, 2025 *Innovations in Cellular Therapies for Cancer, Autoimmune Disease and Other Maladies*, Primer in Precision Pathology, USCSP, Boston, MA.
295. April, 2025 *Innovations in Cellular Therapies for Cancer, Autoimmune Disease and Other Maladies*, 2024-2025 Distinguished Professor Recipient, University of Colorado School of Medicine, Aurora, CO.
296. April, 2025 *Innovations in Cellular Therapies for Cancer, Autoimmune Disease and Other Maladies*, Keynote Speaker, Research Recognition Day, Temple University School of Pharmacy, Philadelphia, PA.
297. May, 2025 *GFR α 4 as a CAR-T Cell Target for the Treatment of Medullary Thyroid Cancer*, Cellicon Valley '25: The Future of Cell and Gene Therapies, Philadelphia, PA.
298. May, 2025 *Personal Experiences that Inspired the Science*, 2025 Margot S. Kruskall Symposium: A Tribute and Scientific Symposium Honoring Dr. Leslie E. Silberstein, Brigham and Women's Hospital, Boston, MA.
299. May, 2025 *Transfusion Medicine and Therapeutic Pathology*, HUP 150th Anniversary: The History of Pathology and Laboratory Medicine at Penn Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA.
300. May, 2025 *From student to physician-researcher: Personal stories that inspired the science*, Jefferson MD/PhD Program's Spring Mentorship Dinner, Thomas Jefferson University, Philadelphia, PA.
301. May, 2025 *Developing a Droolbox for Canine Immunotherapies*, Center for Cellular Immunotherapies Data Session, University of Pennsylvania, Philadelphia, PA.

Organizing Roles in Scientific Meetings:

- | | |
|------------------------|--|
| Nov 1999- July 2001 | Coordinator, 4 th International Workshop on Monoclonal Antibodies Against Human Red Blood Cells and Related Antigens, Paris (meeting July 20-21, 2001). |
| Oct 2004- May 2006 | Scientific Program Co-coordinator, 27 th Annual Meeting of the American Society for Apheresis, Las Vegas, NV (meeting May 25-27, 2006). |

- Feb 2005-
Oct 2005 Program Coordinator, “Applications of Phage Display to Blood Transfusion Medicine”, Annual Meeting of the American Association of Blood Banks, Seattle, WA (meeting October 15-18, 2005).
- Jan 2009-
Jun 2009 Co-coordinator, Immunology Workshop, International Pemphigus Meeting, Berne, Switzerland (meeting June 26-29, 2009).
- Nov 2009-
Apr 2010 Co-coordinator, New Frontiers in Transfusion Medicine, Brown University, Providence, R.I. (meeting April 24, 2010).
- July 2011-
Oct 2011 Program Coordinator, “Hit and Run” Gene/Cell Therapy Protocol for HIV Using Zinc Finger Endonucleases, Scientific Hot Topics in Transfusion Medicine, Annual Meeting of the American Association of Blood Banks, San Diego, CA (meeting October 22-25, 2011)
- June 2012-
May 2013 Scientific Program Coordinator, 34th Annual Meeting of the American Society for Apheresis, Denver, CO (meeting May 22-25, 2013).
- Nov 2013-
Oct 2014 Workshop on CAR T Cell Adoptive Therapies: Product Engineering to Clinical Outcomes, 2014 Annual Meeting of the AABB, Philadelphia, PA

Bibliography:

Research Publications, peer reviewed:

1. Palatt P.J., Prusch R.D., **Siegel D.L.**: The diffusional and osmotic water permeability of the hindgut cuticle of larval *Sarcophaga bullata*, *J Insect Physiology* 23:1113-1116, 1977.
2. **Siegel D.L.**, Goodman S.R., Branton D.: The effect of endogenous proteases on the spectrin binding proteins of human erythrocytes, *Biochimica Biophysica Acta* 598:517-527, 1980.
3. **Siegel D.L.**: Human erythrocyte band 4.9, Ph.D. Thesis, Harvard University, 1983.
4. **Siegel D.L.**, Branton D.: Partial purification and characterization of an actin-bundling protein, band 4.9, from human erythrocytes, *J Cell Biology* 100:775-785, 1985.
5. **Siegel D.L.**, Fox I., Asplund M., Dafoe D., Power M., Zellers L., Barker C.F., Prystowsky M.: Distinguishing rejection from CMV infection in renal transplant recipients using flow cytometry, *Clinical Immunol Immunopath* 51:157-171, 1989.
6. **Siegel D.L.**, Edelstein P.H., Nachamkin I.: Inappropriate utilization of microbiologic tests for the diagnosis of diarrheal disease in hospitalized adult patients, *JAMA* 263:979-982, 1990.
7. **Siegel D.L.**, Silberstein L.E.: Expression and characterization of recombinant anti-Rh(D) antibodies on filamentous phage: A model system for isolating human red cell antibodies by repertoire cloning, *Blood* 83:2334-2344, 1994.

8. Czerwinski M, **Siegel D.L.**, Moore J.S., Spitalnik P.F., Spitalnik S.L.: Construction of bacteriophage expressing mouse monoclonal Fab fragments against the human MN glycophorin blood group antigens, *Transfusion* 35:137-144, 1995.
9. **Siegel D.L.**: Isolation of human anti-red blood cell antibodies by repertoire cloning, *Annals of the New York Academy of Sciences* 764:547-558, 1995.
10. Wojczyk B.S., Czerwinski M., Stwora-Wojczyk M.M., **Siegel D.L.**, Abrams W.R., Wunner W.H., Spitalnik S.L.: Purification of a secreted form of recombinant rabies virus glycoprotein: Comparison of two affinity tags, *Protein Expression and Purification* 7:183-193, 1996.
11. Pereira S., Van Belle P., Elder D., Maruyama H., Jacob L., Sivanandham M., Wallack M., **Siegel D.L.**, and Herlyn D.: Combinatorial antibodies against human malignant melanoma, *Hybridoma* 16:11-16, 1997.
12. Pereira S., Maruyama H., **Siegel D.L.**, Van Belle P., Elder D., Curtis P., Herlyn D.: A model system for detection and isolation of a tumor cell surface antigen using antibody phage display, *J Immunological Methods* 203:11-24, 1997.
13. **Siegel D.L.**, Chang, T.Y., Russell, S., Bunya, V.Y.: Isolation of cell surface-specific human monoclonal antibodies using phage display and magnetically-activated cell sorting: Applications in immunohematology, *J Immunological Methods* 206:73-85, 1997.
14. Wang L., Radic M.Z., **Siegel D.L.**, Chang T., Bracy J., Galili U.: Cloning of anti-Gal Fabs from combinatorial phage display libraries: Comparison of Fab expression in pComb3H and pComb8 phage, *Molecular Immunology* 34:609-618, 1997.
15. **Siegel D.L.**: The human immune response to red blood cell antigens as revealed by repertoire cloning, *Immunologic Research* 17:239-251, 1998.
16. Chang T.Y., **Siegel D.L.**: Genetic and immunological properties of phage-displayed human anti-Rh(D) antibodies: Implications for Rh(D) epitope topology, *Blood* 91:3066-3078, 1998.
17. Czerwinski M., Siemaszko D., **Siegel D.L.**, Spitalnik S.L.: Only selected light chains combine with a given heavy chain to confer specificity for a model glycopeptide antigen, *J Immunology* 160:4406-4417, 1998.
18. Czerwinski M., Krop-Watorek A, **Siegel D.L.**, Spitalnik S.L. A molecular approach for isolating high affinity Fab fragments useful in blood group serology, *Transfusion* 39:364-371, 1999.
19. Arepally G.M., Kamei S., Park K.S., Kamei K., Li Z.Q., Liu W., **Siegel D.L.**, Kisiel W., Cines D.B., Poncz M.: Preparation and characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia (HIT) antibodies, *Blood* 93: 110-118, 2000. (Plenary Paper)
20. Chang T.Y., **Siegel D.L.**: Isolation of an anti-B IgG from a Fab-phage display library, *Transfusion* 41:6-12, 2001.

21. Roark J.H., Bussel J.B., Cines D.B., **Siegel D.L.**: Genetic analysis of autoantibodies in ITP reveals evidence of clonal expansion and somatic mutation, *Blood* 100:1388-1398, 2002.
22. Westhoff C.M., Burd C., **Siegel D.L.**, Foskett J.K.: Evidence that the erythrocyte Rh-blood group glycoprotein functions as an NH₄⁺/H⁺ exchanger, *J Biol Chem* 279:17443-17448, 2004.
23. Silverman G.J., Goodyear C.S., and **Siegel D.L.**: On the mechanism of Staphylococcal protein A immunomodulation, *Transfusion* 45:274-280, 2005.
24. Payne A.S., Ishii K., Kacir S., Lin C., Li H., Hanakawa Y., Tsunoda K., Amagai M., Stanley J.R., **Siegel D.L.**: Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display, *J Clinical Invest* 115:888-899, 2005.
25. Andreadis C., Schuster S.J., Chong E.A., Svoboda J., Luger S.M., Porter D.L., Tsai D.E., Nasta S.D., Elstrom R.L., Goldstein S.C., Downs L.H., Mangan P.A., Cunningham K.A., Hummel K.A., Gimotty P.A., **Siegel D.L.**, Glatstein E., Stadtmauer E.A.: Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma, *Bone Marrow Transplantation* 36:955-961, 2005.
26. Kucher C., Steere J., Elenitas R., **Siegel D.L.**, Xu X.: Nephrogenic fibrosing dermatopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure, *J Amer Acad Derm* 54:S31-4, 2006.
27. Svoboda J., Andreadis C., Elstrom R., Chong E.A., Downs L.H., Berkowitz A., Luger S.M., Porter D.L., Nasta S., Tsai D., Loren A.W., **Siegel D.L.**, Glatstein E., Alavi A., Stadtmauer E.A., Schuster S.J.: Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation, *Bone Marrow Transplantation* 38:211-216, 2006.
28. Payne A.S., **Siegel D.L.**, and Stanley J.R.: Targeting pemphigus autoantibodies through their heavy chain variable region genes, *J Invest Dermatol* 127:1681-1691, 2007.
29. Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Lorem AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, **Siegel DL**, Glatstein E, Stadtmauer EA: Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus docorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support, *American J of Hematol* 82:1071-1075, 2007.
30. Ishii K., Lin C., **Siegel D.L.**, Stanley J.R.: Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies, *J Invest Dermatol* 128:939-948, 2008.
31. Olin R.L., Vogl D.T., Porter D.L., Luger S.M., Schuster S.J., Tsai D.E., **Siegel D.L.**, Cook R.J., Mangan P.A., Cunningham K., Stadtmauer E.A.: Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma, *Bone Marrow Transplantation* 43:417-422, 2009.
32. Yamagami J., Kacir S., Ishii K., Payne A.S., **Siegel D.L.**, Stanley J.R.: Antibodies to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned from individuals without pemphigus, *J Immunol* 183:5615-5621, 2009.

33. Stanley J.R., Ishii K., **Siegel D.L.**, Payne A.S.: Update on the cloning of monoclonal anti-desmoglein antibodies from human pemphigus patients: Implications for targeted therapy. *Veterinary Dermatol* 20:327-330, 2009.
34. Nazha A., Cook R., Vogl D.T., Mangan P.A., Gardler M., Hummel K., Cunningham K., Luger S.M., Porter D.L., Shuster S., O'Doherty U., **Siegel D.**, Stadtmauer E.A.: Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen, *Bone Marrow Transplantation* 46:59-63, 2010.
35. Mangalmurti N.S., Chatterjee S., Chen G. Anderson E., Mohammed A., **Siegel D.L.**, Schmidt A.M., Albelda S.M., Lee J.S.: Advanced glycation endproducts on stored erythrocytes increase endothelial reactive oxygen species generation through interaction with RAGE, *Transfusion* 50:2352-2361, 2010.
36. Yamagami J., Payne A., Kacir S., Ishii K., **Siegel D.L.**, Stanley J.R.: Homologous regions of autoantibody heavy chain complementarity-determining region 3 (H-CDR3) in patients with pemphigus cause pathogenicity, *J Clin Invest* 120:4111-4117, 2010.
37. Adamski J., Jamensky L., Ross J., **Siegel D.L.**, Sachais B.: Anaphylactoid-like reactions in a patient with hyperLp(a)lipidemia undergoing liposorber therapy and homeotherapy with the spice turmeric, *J Clin Apheresis* 25:354-357, 2010.
38. Zhao A., Nunez-Cruz S., Li C., Coukos G., **Siegel D.L.**, Scholler N. : Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform., *J Immunol Meth* 363:221-232, 2011.
39. Braganza A., Wallace K., Pell L., Parrish C.R., **Siegel D.L.**, Mason N.J.: Generation and validation of canine single chain Fragment variable phage display libraries, *Veterinary Immunol & Immunopathol* 139:27-40, 2011.
40. Wang L., Calcedo R., Bell P., Lin J., Grant R., **Siegel D.L.**, Wilson J.M.: Impact of natural infections with adeno-associated viruses on safety and efficacy of gene therapy, *Human Gene Therapy* 22:1389-1401, 2011.
41. Dangaj D., Abbott K., Mookerjee A., Zhao A., Kirby P.S., Sandaltzopoulos R., Powell D.J., Lamaziere A., **Siegel D.L.**, Wolf C., Scholler N.: Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody, *PLoS ONE*, 6:e28386, 2011.
42. Li Y., **Siegel D.L.**, Scholler N., Kaplan D.E.: Glypican-3-specific scFv isolation and validation for use in hepatocellular carcinoma, *BMC Biotechnology*, 12:23, 2012.
43. Kouno M., Lin C., Schechter N., **Siegel D.L.**, Stanley J.R.: Targeted delivery of tumor necrosis factor-related apoptosis-inducing ligand to keratinocytes with a pemphigus monoclonal antibody, *J Invest Dermatol*, 133:2212-2220, 2013.
44. Mangalmurti N.S., Friedman J.L., Wang L.C., Stolz D.B., Muthukumar G., **Siegel D.L.**, Schmidt A.M., Lee J.S., Albelda S.M.: The receptor for advanced glycation end products

- mediates lung endothelial activation by RBCs, *Am J Physiol - Lung Cell Mol Physiol* 304:L250-263, 2013.
45. Gao, C., Liu, Y., Zhang, H., Zhang, Y., Fukuda, M.N., Palma, A.S., Kozak, R.P., Childs, R.A., Nonaka, M., Li, Z., **Siegel, D.L.**, Hanfland, P., Peehl, D.M., Chai, W., Greene, M.I., Feizi, T.: Carbohydrate sequence of the prostate cancer-associated antigen F77 assigned by a mucin O-glycome designer array, *J Biol Chem* 289:16462-16477, 2014.
 46. Hammers, C.M., Chen, J., Lin, C., Kacir, S., **Siegel, D.L.**, Payne, A.S., Stanley, J.R.: Persistence of anti-desmoglein 3 IgG+ B-cell clones in pemphigus patients over years, *J Invest Dermatol* 135:742-749, 2015.
 47. Rapoport, A.P., Stadtmauer, E.A., Binder-Scholl, G.K., Goloubeva, O., Vogl, D.Y., Lacey, S., Badros, A.Z., Garfall, A., Weiss, B., Finklestein, J., Kulikovskaya, I., Sinha, S.K., Kronsberg, S., Gupta, M., Bond, S., Melchiori, L., Brewer, J.E., Bennett, A.D., Gerry, A.B., Pumphrey, N.J., Williams, D., Tayton-Martin, H.K., Ribeiro, L., Holdich, T., Yanovich, S., Hardy, N., Yared, J., Kerr, N., Philip, S., Westphal, S., **Siegel, D.L.**, Levine, B.L., Jakobsen, B.K., Kalos, M., June, C.H. : NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma, *Nature Medicine* 21:914-921, 2015.
 48. Pickens, B., Mao, Y., Li, D., **Siegel, D.L.**, Poncz, M., Cines, D.B., Zheng, X.L.: Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models, *Blood* 125:3326-3334, 2015.
 49. Casina, V.C., Hu, W., Mao, J., Lu, R.-N., Hanby, H.A., Pickens, B., Kan, Z., Lim, W.K., Mayne, L., Ostertag, E., Kacir, S., **Siegel, D.L.**, Englander, S.W., Zheng, X.L. : High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome, *PNAS (USA)*, 112:9620-9625, 2015.
 50. Polak, K., Acierno, M., Raj, K., Mizukamo, K., **Siegel, D.L.**, Giger, U.: Dog Erythrocyte Antigen 1 (DEA 1): Mode of inheritance and initial characterization, *Vet Clin Pathol*, 44: 369-379, 2015.
 51. Fuentes, R.E., Zaytsev, S., Sook Ahn, H., Hayes, V., Kowalska, M.A., Lambert, M.P., Wang, Y., **Siegel, D.L.**, Bougie, D.W., Aster, R.H., Myers, D.D., Stepanova, V., Cines, D.B., Muzykantov, V.R., Poncz, M. : A chimeric platelet-targeted urokinase prodrug selectively blocks new thrombus formation, *J Clin Invest*, 126:483-494, 2016.
 52. Ostertag, E., Kacir, S., Thiboutot, M., Gulendran, G., Zheng, X.L., Cines, D.B., **Siegel, D.L.**: ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization *in vitro*, *Transfusion*, 56:1763-1774, 2016.
 53. Ostertag, E., Bdeir, K., Kacir, S., Thiboutot, M., Gulendran, G., Yunk, L., Hayes, V., Motto, D., Poncz, M., Zheng, X.L., Cines, D.B., **Siegel, D.L.**: ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model, *Transfusion*, 56:1775-1785, 2016. (recipient of the **Research Innovation in Scientific Excellence (RISE) Award** from the AABB for best original research article published in *Transfusion* in the 2016)

54. Gronwall, C., Clancy, R.M., Getu, L., Lloyd, K.A., **Siegel, D.L.**, Reed, J.H., Buyon, J.H., Silverman, G.J.: Modulation of natural IgM autoantibodies to oxidative stress-related neo-epitopes on apoptotic cells in newborns of mothers with anti-Ro autoimmunity. *J Autoimmun*, 73:30-41, 2016.
55. Chen, J., Zheng, Q., Hammers, C.M., Ellebrecht, C., Mukherjee, C., Tang, H-Y., Lin, C., Yuan, H-J., Pan, M., Langenhan, J., Komorowski, L., **Siegel, D.L.**, Payne, A.S., Stanley, J.R.: Proteomic analysis of pemphigus autoantibodies indicates a much larger, more diverse, and dynamic repertoire than determined by B-cell genetics, *Cell Reports*, 18:237-247, 2017.
56. Carnemolla, R., Villa, C.H., Greineder, C.F., Zaitsev, S., Kowalska, A., Atochin, D.N., Cines, D.B., **Siegel, D.L.**, Esmon, C.T. Muzykantov, V.R.: Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury, *FASEB J.*, 31:761-770, 2017.
57. Beigel, J.H., Tebas, P., Elie-Turenne, Marie-Carmelle, et al.: Immune plasma for the treatment of severe influenza: an open-label, multicenter, phase 2 randomised study, *The Lancet Respiratory Medicine*, 5:500-511, 2017.
58. Villa, C.H., Pan, D.C., Johnston, I., Greineder, C.F., Walsh, L., Hood, E., Cines, D.B., Poncz, M., **Siegel, D.L.**, Muzykantov, V.R.: Biocompatible coupling of therapeutic fusion proteins to human erythrocytes, *Blood Advances*, 2:165-176, 2018.
59. Fraietta, J.A., Lacey, S.F., Orlando, E.J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A.C., Wang, Y., O'Connor, R.S., Hwang, W.-T., Pequignot, E., Ambrose, D.E., Zhang, C., Wilcox, N., Bedoya, F., Dorfmeir, C., Chen, F., Tian, L., Parakandi, H., Gupta, M., Young, R.M., Johnson, F.B., Kulikovskaya, I., Liu, L., Xu, J., Kassim, S.H., Suhoski-Davis, M.M., Levine, B.L., Frey, N.V., **Siegel, D.L.**, Huang, A.C., Wherry, E.J., Bitter, H., Brogdon, J.L., Porter, D.L., June, C.H., Melenhorst, J.J.: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia, *Nature Medicine*, 24:563-571, 2018.
60. Garfall, A., Stadtmauer, E., Hwang, W.-T., Lacey, S., Melenhorst, J., Krevvata, M., Carroll, M., Matsui, W., Wang, Q., Dhodapkar, M., Dhodapkar, K., Das, R., Vogl, D., Weiss, B., Cohen, A., Mangan, P., Ayers, E., Nunez-Cruz, S., Kulikovskaya, I., Davis, M., Lamontagne, A., Dengel, K., Kerr, N., Young, R., **Siegel, D.L.**, Levine, B., Milone, M.C., Maus, M., June, C.H.: Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma, *JCI Insight*, 3:e120505, 2018.
61. Cohen, A., Garfall, A., Stadtmauer, E., Melenhorst, J., Lacey, S., Lancaster, E., Vogl, D., Weiss, B., Dengel, K., Nelson, A. M., Plesa, G., Chen, F., Davis, M., Hwang, W.-T., Young, R., Brogdon, J., Isaacs, R., Pruteanu-Malinici, I., **Siegel, D. L.**, Levine, B., June, C. H., Milone, M.C.: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma, *J Clin Invest*, 129:2210-2221, 2019.
62. Gutjahr, A., Heck, F., Emtenani, S., Hammers, A.-K., Hundt, J.E., Muck, P., **Siegel, D.L.**, Schmidt, E., Stanley, J.R., Zillikens, D., Hammers, C.M.: Bullous pemphigoid autoantibody-mediated complement fixation is abolished by the low molecular-weight heparin tinzapatin sodium, *Brit J Dermatol*, 181:593-594, 2019.

63. Garfall, A.L., Dancy, E., Cohen, A.D., Hwang, W.-T., Fraietta, J., Davis, M.M., Levine, B.L., **Siegel, D.L.**, Stradtmauer, E., Vogl, D.T., Waxman, A., Rapoport, A.P., Milone, M., June, C.H., Melenhorst, J.J.: T cell phenotypes associated with effective CAR T cell therapy in post-induction versus relapsed multiple myeloma, *Blood Advances*, 3:2812-2815, 2019.
64. Chong, E.A., Levine, B.L., Grupp, S.A., Davis, M.M., **Siegel, D.L.**, Maude, S.L., Gladney, W.L., Frey, N.V., Porter, D.L., Hwang, W.-T., Chong, E.R., June, C.H., Schuster, S.J. CAR T cell viability release testing and clinical outcomes: is there a lower limit?, *Blood*, 134:1873-1875, 2019.
65. Nobles, C., Sherrill-Mix, S., Everett, J.K., Reddy, S., Fraietta, J., Porter, D., Frey, N., Gill, S.I., Grupp, S., Maude, S., **Siegel, D.L.**, Levine, B.L. June, C.H., Lacey, S., Melenhorst, J., Bushman, F.: CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration, *J Clin Invest*, 130:673-685, 2020.
66. Choi, H., Kudchodkar, S.B., Reuschel, E.L., Asija, K., Borole, P., Agarwal, S., Van Gorder, L., Reed, C.C., Gulendram, G., Ramos, S., Broderick, K.E., Kim, J.J., Ugen, K.E., Kobinger, G., **Siegel, D.L.**, Weiner, D.B., Muthumani, K.: Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge, *Human Vaccines & Immunotherapeutics*, 16:907-918, 2020.
67. He, X., Feng, Z., Ma, J., Ling, S., Cao, Y., Gurung, B., Wu, Y., Katona, B.W., O'Dwyer, K., **Siegel, D.L.**, June, C.H., Hua, X.: Bi-specific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia, *Blood*, 135:713-723, 2020.
68. Stadtmauer, E.A., Fraietta, J.A., Davis, M.M., Cohen, A.D., Weber, K.L., Lancaster, E., Mangan, P.A., Kulikovskaya, I., Gupta, M., Chen, F., Tian, L., Gonzalez, V.E., Xu, J., Jung, I.Y., Melenhorst, J.J., Plesa, G., Shea, J., Matlawski, T., Cervini, A., Gaymon, A.L., Desjardins, S., Lamontagne, A., Salas-Mckee, J., Fesnak, A., **Siegel, D.L.**, Levine, B.L., Jadowsky, J.K., Young, R.M., Chew, A., Hwang, W.-T., Hexner, E.O., Carreno, B.M., Nobles, C.L., Bushman, F.D., Parker, K.R., Qi, Y., Satpathy, A.T., Chang, H.Y., Zhao, Y., Lacey, S.F., June, C.H.: CRISPR-engineered T cells in patients with refractory cancer, *Science*, 367:eaba7365, 2020.
69. Diorio, C., Shaw, P.A., Pequignot, E., Orlenko, A., Chen, F., Aplenc, R., Barrett, D.M., Bassiri, H., Behrens, E., DiNofia, A.M., Gonzalez, V., Koterba, N., Levine, B.L., Maude, S.L., Meyer, N.J., Moore, J.H., Paessler, M., Porter, D.L., Bush, J.L., **Siegel, D.L.**, Davis, M.M., Zhang, D., June, C.H., Grupp, S.A., Melenhorst, J.J., Lacey, S.F., Weiss, S.L., Teachey, D.T.: Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children, *Blood Adv.*, 4:5174-5183, 2020.
70. Bhoj, V., Li, L., Parvathaneni, K., Zhang, Z., Kacir, S., Arhontoulis, D., Zhou, K., McGettigan-Croce, B., Nunez-Cruz, S., Gulendran, G., Boesteanu, A.C., Johnson, L., Feldman, M.D., Radaelli, E., Mansfield, K., Nasrallah, M., Goydel, R., Peng, H., Rader, C., Milone, M.C., **Siegel, D.L.**: Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4 (GFR α 4), *Molecular Therapy – Oncolytics*, 20:387-398, 2021.
71. Tebas, P., Jadowsky, J.K., Shaw, P.A., Tian, L., Esparza, E., Brennan, A., Kim, S., Naing, S.Y., Richardson, M.W., Vogel, A.N., Maldini, C., Kong, H., Liu, X., Lacey, S.F., Bauer, A.M., Mampe, F., Lee, G., Dale Ando, D., Levine, B.D., Porter, D.L., Zhao, Y., **Siegel, D.L.**,

- Bar, K.J., June, C.H., Riley, J.L.: CCR5-edited CD4 T cells augment HIV-specific immunity to enable post rebound control of HIV replication, *J. Clin. Invest.*, 131:e144486, 2021.
72. Halkidis, K., **Siegel, D.L.**, Zheng, X.L.: A human monoclonal antibody against the C-terminus of ADAMTS13 modulates its susceptibility to an inhibitor in thrombotic thrombocytopenic purpura, *J. Thromb Haemos*, 19:1888-1895, 2021.
73. Myers, R.M., Li, Y., Leahy, A.B., Barrett, D.M., Teachey, D.T., Callahan, C., Fasano, C.C., Rheingold, S.R., DiNofia, A., Wray, L. Aplenc, R., Baniewicz, D., Liu, H., Shaw, P.A., Pequignot, E., Getz, K.D., Brogdon, J.L., Fesnak, A.D., **Siegel, D.L.**, Davis, M.M., Bartoszek, C., Lacey, S.F., Hexner, E.O., Chew, A., Wertheim, G.B., Levine, B.L., June, C.H., Grupp, S.A., Maude, S.L.: Humanized CD19-targeted Chimeric Antigen Receptor (CAR) T cells in CAR-naïve and CAR-exposed children and young adults with relapsed/refractory acute lymphoblastic leukemia, *J. Clin. Oncol.*, 39:3044-3055, 2021.
74. Tutwiler, V., Litvinov, R.I., Protopopova, A., Nagaswami, C., Villa, C., Abdulmalik, O., **Siegel, D.L.**, Eric Russell, E.R., Muzykantov, V.R., Lam, W.A., Myers, D.R., Weisel, J.W.: Pathologically stiff erythrocytes can promote thrombosis by impeding contraction of blood clots, *J. Thromb. Haemost.*, 19:2894-2895, 2021.
75. Bar, K.J., Shaw, P.A., Choi, G.H., Aqui, N., Fesnak, A., Yang, J.B., Soto-Calderon, H., Grajales, L., Starr, J., Andronov, M., Mastellone, M., Amonu, C., Feret, G., DeMarshall, M., Buchanan, M., Caturla, M., Gordon, J., Wanicur, A., Monroy, M.A., Mampe, F., Lindemuth, E., Gouma, S., Mullin, A.M., Barilla, H., Pronina, A., Irwin, L., Thomas, R., Eichinger, R.A., Demuth, F., Luning Prak, E.T., Pascual, J.L., Short, W., Elovitz, M.A., Baron, J., Meyer, N.J., Degnan, K.O., Frank, I., Hensley, S., **Siegel, D.L.**, Tebas, P.: A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia, *J. Clin. Invest.*, 131:e15511, 2021.
76. Mason, N.J., Chester, N., Xiong, A., Rotolo, A., Wu, Y., Glassman, P., Gulendan, G., **Siegel, D.L.**: Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors, *mAbs*, 13:e2004638, 2021.
77. Melenhorst, J.J., Chen, G.M., Wang, M., Porter, D.L., Gao, P., Bandyopadhyay, S., Pruteanu-Malinici, I., Nobles, C.L., Maji, S., Frey, N.V., Gill, S.I., Tian, L., Kulikovskaya, I., Gupta, M., Davis, M.M., Fraietta, J.A., Brogdon, J.L., Young, R.M., Ambrose, D.E., Chew, A., Levine, B.L., **Siegel, D.L.**, Alanio, C., Wherry, E.J., Bushman, F.D., Lacey, S.F., Tan[†] K., June C.H.: Decade-long remissions of leukemia sustained by the persistence of activated CD4⁺ CAR T-cell, *Nature*, 602:503-509, 2022.
78. Narayan, V., Barber-Rotenberg, J.S., Jung, I.Y., Lacey, S.F., Rech, A.J., Davis, M.M., Hwang, W.-T., Lai, P., Carpenter, E.L., Maude, S.L., Plesa, G., Vapiwala, N., Chew, A., Moniak, M., Sebro, R.A., Farwell, M.D., Marshall, A., Gilmore, J., Lledo, L., Dengel, K., Church, S.e., Hether, T.D., Xu, J., Gohil, M., Buckingham, T.H., Yee, S.S., Gonzalez, V.E., Kulikovskaya, I., Chen, F., Tian, L., Tien, K., Gladney, W., Nobles, C.L., Raymond, H., Prostate Cancer Cellular Therapy Program Investigators, Hexner, E.O., **Siegel, D.L.**, Bushman, F.D., June, C.H., Fraietta, J.A., Haas, N.B. PSMA-redirected TGFβ-insensitive armored CAR T cell to treat metastatic castration resistant prostate cancer, *Nature Medicine*, 28:724-734, 2022.

79. Feng, Z., He, X., Zhang, X., Wu, Y., Xing, B., Knowles, A., Shan, Q., Miller, S., Hojnacki, T., Ma, J., Katona, B.W., Gade, T.P.F., **Siegel, D.L.**, Schrader, J., Metz, D.C., June, C.H., Hua X.: Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues. *Nature Cancer*, 3:581-594, 2022.
80. Gill, S., Vides, V., Frey, N.V., Hexner, E., Metzger, S., O'Brien, M., Hwang, W-T, Brogdon, J.L., Davis, M.M., Fraietta, J.A., Gaymon, A.L., Gladney, W.L., Lacey, S.F., Lamontagne, A., Mato, A.R., Maus, M.V., Melenhorst, J.J., Pequignot, E., Ruella, M., Shestov, M., Byrd, J.C., Schuster, S.J., **Siegel, D.L.**, Levine, B.L., June, C.H., Porter, D.L.: Anti-CD19 CAR T cells in combination with Ibrutinib for the treatment of chronic lymphocytic leukemia, *Blood Advances*, 6:5774-5785, 2022.
81. Hsueh, Y.-C., Wang, Y., Riding, R.L., Catalano, D.E., Lu, Y.-J., Richmond, J.M., **Siegel, D.L.**, Ruscowski, M., Stanley, J.R., Harris, J.E.: A keratinocyte-tethered biologic enables location-precise treatment in mouse vitiligo, *J. Invest. Dermatol.*, doi: <https://doi.org/10.1016/j.jid.2022.06.007>, 2022.
82. Glassman, P.M., Villa, C.H., Marcos-Contreras, O.A., Hood, E.D., Walsh, L.R., Greineder, C.F., Myerson, J.W., Shuvaeva, T., Puentes, L., Brenner, J.S., **Siegel, D.L.**, Muzykantov, V.R.: Targeted in vivo loading of red blood cells markedly prolongs nanocarrier circulation, *J. Bioconj Chem.*, 33:1286-1294, 2022.
83. Herman, J.D., Wang, C., Burke, J.S., Zur, Y., Compere, H., Kang, J., Macvicar, R., Taylor, S., Shin, S., Frank, I., **Siegel, D.**, Tebas, P., Choi, G.H., Shaw, P.A., Yoon, H., Pirofski, L.A., Juelg, B., Bar, K.J., Lauffenburger, D., Alter, G.: Nucleocapsid-specific antibody function is associated with therapeutic benefit from Covid-19 convalescent plasma, *Cell Reports Med*, doi: <https://doi.org/10.1016/j.xcrm.2022.100811>, 2022.
84. Jung, I.-Y., Narayan, V., McDonald S., Rech, A.J., Bartoszek, R., Hong, G., Davis, M.M., Xu, J., Boesteanu, A.C., Barber-Rotenberg, J.S., Plesa, G., Lacey, S.F., Jadowsky, J.K., **Siegel, D.L.**, Hammill, D., Cho-Park, P.F., Berger, S.L., Haas, N.B., Fraietta, J.A.: BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T-cell stemness and exhaustion, *Science Translational Medicine*, DOI: 10.1126/scitranslmed.abn7336, 2022.
85. Garfall, A., Cohen, A., Susanibar-Adaniya, S., Hwang, W.-T., Vogl, D., Waxman, A., Lacey, S., Gonzalez, V., Fraietta, J.A., Gupta, M., Kulikovskaya, I., Tian, L., Chen, F., Koterba, N., Bartoszek, R.L., Patchin, M., Xu, R., Plesa, G., **Siegel, D.L.**, Brennan, A., Nelson, A.-M., Ferthio, R., Cosey, A., Shea, K.-M., Leskowitz, R., Four, M., Wilson, W., Miao, F., Lancaster, E., Carreno, B., Linette, G., Hexner, E., Young, R., Bu, D., Mansfield, K., Brogdon, J., June, C., Milone, M.C., Stadtmauer, E.: Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy, *Blood Cancer Discovery*, 4:118-133, doi: 10.1158/2643-3230.BCD-22-0074, 2023.
86. Jung, I.-Y., Noguera-Ortega, E., Bartoszek, R., Collins, S.M., Williams, E., Davis, M., Jadowsky, J.K., Plesa, G., **Siegel, D.L.**, Chew, A., Levine, B.L., Berger, S.L., Moon, E.K., Albelda, S.M., Fraietta, J.A. Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors, *Cell Reports Medicine*, 4, 101053 2023.

87. Halkidis, K., Meng, C., Liu, S., Mayne, L., **Siegel, D.L.**, Zheng, X.L.: Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura, *Blood*, 141:2993-3005, 2023.
88. Jung, I.-Y., Bartoszek, R.L., Rech, A., Collins, S.M., Ooi, S.-K., Williams, E.F., Hopkins, C., Narayan, V., Haas, N.B., Frey, N.V., Hexner, E.O., **Siegel, D.L.**, Plesa, G., Porter, D.L., Cantu, A., Everett, J.K., Guedan, S., Berger, S.L., Bushman, F.D., Herbst, F., Fraietta, J.A.: Type I interferon signaling via the EGR2 transcriptional regulator potentiates CAR T cell-intrinsic dysfunction, *Cancer Discovery*, 13:1636-1655, 2023.
89. Yoshimoto, S., Chester, N., Xiong, A., Radaelli, E., Wang, H., Brillantes, M., Gulendran, G., Glassman, P., **Siegel, D.L.**, Mason, N.J.: Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors, *mAbs*, 13:e2004638-1 to e2004638-11, 2023.
90. Mack, E.A., Dougher, M.C., Ginda, A., Cahill, C., Murter, M., Schell, K., Tanhehco, Y.C., Bhoj, V.G., Fesnak, A.D., **Siegel, D.L.**, Kambayashi, T., Aqui, N.A., O'Doherty, U.: Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis, *Blood*, 143:1049-1054, 2024.
91. Bagley, S.J., Logun, M., Fraietta, J.A., Wang, X., Desai, A.S., Bagley, L.J., Nabavizadeh, A., Jarocha, D., Martins, R., Maloney, E., Lledo, L., Stein, C., Marshall, A., Leskowitz, R., Jadowsky, J.K., Christensen, S., Oner, B.S., Plesa, G., Brennan, A., Gonzalez, V., Chen, F., Sun, Y., Gladney, W., Barrett, D., Nasrallah, M.P., Hwang, W.-T., Ming, G.-L., Song, H., **Siegel, D.L.**, June, C.H., Hexner, E.O., Binder, Z.A., O'Rourke, D.M.: Intrathecal bivalent CAR T cells targeting EGFR and IL13Ra2 in recurrent glioblastoma: Phase 1 trial interim results, *Nature Medicine*, 30:1320-1329, 2024.
92. Bhagwat, A.S., Torres, L., Shestova, O., Shestov, M., Mellors, P.W., Fisher, H.R., Farooki, S.N., Frost, B.F., Loken, M.R., Gaymon, A.L., Frazee, D., Rogal, W., Frey, N., Hexner, E.O., Luger, S.M., Loren, A.W., Martin, M.E., McCurdy, S.R., Perl, A.E., Stadtmauer, E., Brogdon, J.L., Fraietta, J.A., Hwang, W.T., **Siegel, D.L.**, Plesa, G., Aplenc, R., Porter, D.L., June, C.H., Gill, S.I.: Cytokine-mediated CAR T therapy resistance in AML, *Nature Medicine*, 2024, Sep 27. doi.org/10.1038/s41591-024-03271-5
93. Logun, M., Wang, X., Sun, Y., Bagley, S.J., Li, N., Desai, A., Zhang, D.Y., Nasrallah, M.P., Pai, E. L.-L., Oner, B.S., Plesa, G., **Siegel, D.L.**, Binder, Z.A., Ming, G-I, Song, H., O'Rourke, D.M.: Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy, *Cell Stem Cell*, 32:1-10, 2024.
94. Jadowsky, J.K., Hexner, E.O., Marshall, A., Grupp, S.A., Frey, N.V., Riley, J.L., Veloso, E., McConville, H., Rogal, W., Czuczman, C., Hwang, W.-T., Li, Y., Leskowitz, R.M., Farrelly, O., Karar, J., Christensen, S., Barber-Rotenberg, J., Gaymon, A., Aronson, N., Bernstein, W., Melenhorst, J.J., Roche, A.M., Everett, J.K., Zolnoski, S.A., McFarland, A.G., Reddy, S., Petrichenko, A., Cook, E.J., Lee, C., Gonzalez, V.E., Alexander, K., Kulikovskaya, I., Ramirez-Fernandez, A., Minehart, J.C., Ruella, M., Gill, S.I., Schuster, S.J., Cohen, A.D., Garfall, A.L., Shah, P.D., Porter, D.L., Maude, S.L., Levine, B.L., **Siegel, D.L.**, Chew, A., McKenna, S., Lledo, L., Davis, M.M, Plesa, G., Herbst, F., Stadtmauer, E.A., Tebas, P., DiNofia, A., Haas, A., Haas, N.B., Myers, R., O'Rourke, D.M., Svoboda, J., Tanyi, J.L., Aplenc, R., Jacobson, J.M., Ko, A.H., Cohen, R.B., June, C.H., Bushman, F.D., Fraietta, J.A.:

Long-term safety analysis in 783 patients treated with lentiviral or gammaretroviral gene-modified T-cells, *Nature Medicine*, <https://doi.org/10.1038/s41591-024-03478-6>, 2025.

95. Svoboda, J., Landsburg, D.J., Gerson, J., Nasta, S.D., Barta, S.K., Chong, E.A., Cook, M., Frey, N.V., Shea, J., Cervini, A., Marshall, A., Four, M., Davis, M.M., Jadowski, J.K., Chew, A., Pequignot, E., Gonzalez, V., Noll, J.H., Paruzzo, L., Rojas-Levine, J., Plesa, G., Schollar, J., **Siegel, D.L.**, Levine, B., Porter, D.L., Ghassemi, S., Ruella, M., Rech, A., Leskowitz, R.M., Fraietta, J.A., Hwang, W.-T., Hexner, E., Schuster, S.J., June, C.H.: Enhanced CAR T-cell therapy for lymphoma after previous failure, *New England J Med*, 392:1824-1835, 2025.
96. Ramirez-Fernández, A., Dimitri, A., Chen, F., Bartoszek, R., Chen, G., Córdoba-Espejo, L., Zhou, Y., Tang, Y.H., Lin, C.-T., Acosta, R., Scholler, J., Ghilardi, G., Porazzi, P., Pellicer, M., Profitós-Pelejà, N., Barta, S., Chew, A., Jadowsky, J., Vanessa Gonzalez, V., Siegel, D.L., Levine, B., Roué, G., Ruella, M., Lotze, M., June, C.H., Riley, J., Fraietta, J.: Gene-targeted universal allogeneic gamma-delta CAR T cells for cancer immunotherapy, *Nature Biomedical Engineering*, *in press*.
97. Myers, R.M., DiNofia, A.M., Li, Y., Diorio, C., Liu, H., Wertheim, G., Fraietta, J.A., Gonzalez, V., Plesa, G., **Siegel, D.L.**, Iannone, E., Shinehouse, L., Brogdon, J.L., Taylor, C., Jadowsky, J.K., Hexner, E.O., Engels, B., Baniewicz, D., Callahan, C., Ruella, M., Aplenc, R., Leahy, A.B., McClory, S.E., Rheingold, S.R., Wray, L., June, C.H., Maude, S.L., Frey, N.V., Grupp, S.A.: CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy, *J ImmunoTherapy Cancer*, *in press*.
98. Bagley, S.J., Desai, A.S., Fraietta, J.A., Silverbush, D., Chafamo, D., Freeburg, N.F., Gopikrishna, G.K., Rech, A.J., Nabavizadeh, A., Bagley, L.J., Park, J., Jarocho, D., Martins, R., Sarmiento, N., Maloney, E., Lledo, L., Stein, C., Marshall, A., Leskowitz, R.M., Jadowsky, J.K., Mackey, S., Christensen, S., Oner, B.S., Plesa, G., Brennan, A., Gonzalez, V., Chen, F., Barrett, D., Colbourn, R., Nasrallah, M.P., Mourelatos, Z., Hwang, W.-T., Alanio, C., **Siegel, D.L.**, June, C.H., Hexner, E.O., Binder, Z.A., O'Rourke, D.M.: Intracerebroventricular bivalent CAR T cells targeting EGFR epitope 806 and IL-13R α 2 in recurrent glioblastoma: a phase 1 dose finding study, *Nature Medicine*, *in press*.
99. Aznar, M.A., Good, C.R., Barber-Rotenberg, J.S., Agarwal, S., Wilson, W., Watts, A., Zhang, Z., Gonzales, D., Donahue, G., Hwang, W.-T., Rennels, A.K., Rech, A.J., Kuramitsu, S., Glastad, K.M., Alexander, K.A., Plesa, G., Brennan, A., **Siegel, D.L.**, Tanyi, J., Haas, A., Drew Torigian, D., Nadolski, G., Gonzalez, V.E., Hexner, E.O., Fraietta, J.A., Jadowsky, J.K., Young, R.M., Berger, S.L., June, C.H., O'Hara, M.H.: Mesothelin-directed CAR T cells for the treatment of patients with unresectable or metastatic pancreatic adenocarcinoma, *submitted*.
100. Chen, G.M., Gering, D., Satulovsky, J., Datta, S., Lai, P., Karar, J., Gonzalez, V.E., Alexander, K., Chew, A., Jadowsky, J.K., Ruella, M., Paruzzo, L., Amses, K.R., Rech, A.J., Stadtmauer, E.A., Frey, N.V., Hexner, E.O., Porter, D.L., Cohen, A.D., Gill, S.I., Garfall, A.L., Schuster, S.J., Mo, K.C., Liang, S.I., Spasic, M., Levine, B.L., **Siegel, D.L.**, Ramírez- Fernández, A., Mackall, C.L., Bushman, F.D., Good, Z., E. John Wherry, E.J., June, C.H., Fraietta, J.A.: Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-hematologic cancer, *submitted*.

Research Publications, non-peer reviewed:

1. Herlyn D., Pereira S., Maruyama H., Van Belle P., Elder D., Jacob L., Somasundaram R., Wallack M., and **Siegel D.L.**: Identification of tumor antigens using antibody phage display. In Thibeault, C. (Ed.) Antibody Engineering: New Technologies, Applications, & Commercialization, Biomedical Library Series, IBC, Boston, 1996.
2. **Siegel D.L.** and Chang T: Isolation of cell surface-specific human monoclonal antibodies using phage display and magnetically-activated cell sorting. In Hori, W. (Ed.) Antibody Engineering II, Biomedical Library Series, IBC, Boston, 1997, 263-272.
3. **Siegel D.L.** Understanding immunogenicity on a molecular level: New insights revealed by the Rh(D) immune response. In The Compendium 1999, American Association of Blood Banks, Bethesda, 1999, 393-396.

Abstracts:

1. **Siegel D.L.**, Branton D.: Human erythrocyte band 4.9. *J Cell Biology*, 95:265a, 1982.
2. **Siegel D.L.**, Branton D.: Human erythrocyte band 4.9, an actin-bundling protein. *J Cell Biology*, 97:279a, 1984.
3. **Siegel D.L.**, Fox I., Asplund M., Dafoe D., Power M., Prystowsky M.: Differential expression of activation antigens on peripheral blood lymphocytes in renal allograft recipients during episodes of rejection and infection. Eighth Annual Philadelphia Regional Immunology Conference, Philadelphia, PA, 1987.
4. **Siegel D.L.**, Fox I., Asplund M., Dafoe D., Power M., Prystowsky M.: Differential expression of activation antigens on peripheral blood lymphocytes in renal allograft recipients during episodes of rejection and infection. American Society of Transplant Physicians, 7th Annual Meeting, Chicago, IL, 1988.
5. **Siegel D.L.**, Fox I., Asplund M., Dafoe D., Power M., Prystowsky M.: Distinguishing rejection from viral infection in renal allograft recipients using flow cytometry. Academy of Clinical Laboratory Physicians and Scientists, Annual Meeting, Cincinnati, OH, 1988.
6. **Siegel D.L.**, Fox I., Asplund M., Dafoe D., Power M., Prystowsky M.: Differential expression of activation antigens on peripheral blood lymphocytes in renal allograft recipients during episodes of rejection and infection. XII International Congress of The Transplantation Society, Sydney, Australia, 1988.
7. Wilding P., **Siegel D.L.**, Perloff L.: Monitoring patients with pancreas transplantation. *Clin Chem*, 34:1204, 1988.
8. **Siegel D.L.**, Fischer S., Lubensky I., Perloff L., Wilding P.: Monitoring patients with pancreas allografts. Academy of Clinical Laboratory Physicians and Scientists, Annual Meeting, Cincinnati, OH, 1988.

9. Guoth M., Murgia A., **Siegel D.L.**, Smith R., Cooke N., Haddad J.: Origin of cell-surface vitamin D-binding protein (Gc-globulin). American Society for Clinical Investigation, Annual Meeting, 1988.
10. **Siegel D.L.**, Fox I., Asplund M., Dafoe D., Power M., Prystowsky M.: Differential expression of activation antigens on peripheral blood lymphocytes in renal allograft recipients during episodes of rejection and infection. Third Annual Conference on Clinical Immunology, San Francisco, CA, 1988.
11. **Siegel D.L.**, Silberstein L.E.: Production of human red cell antibodies in bacteria by repertoire cloning. *Transfusion*, 32(Suppl):45S, 1992 (Plenary Session abstract).
12. **Siegel D.L.**, Silberstein L.E.: Isolation of recombinant human anti-Rh(D) antibodies from libraries expressed on M13 phage. *Transfusion*, 33(Suppl):54S, 1993.
13. Czerwinski M., **Siegel D.L.**, Spitalnik S.L.: Construction of bacteriophage expressing mouse monoclonal anti-N Fab fragments. *Transfusion*, 33(Suppl):53S, 1993.
14. **Siegel D.L.**, Silberstein L.E.: Expression and characterization of recombinant anti-Rh(D) antibodies on filamentous phage: A model system for isolating human red cell antibodies by repertoire cloning. Fourteenth Annual Philadelphia Regional Immunology Conference, Philadelphia, PA, 1993.
15. **Siegel D.L.**, Silberstein L.E.: Expression and characterization of recombinant anti-Rh(D) antibodies on filamentous phage: A model system for isolating human red cell antibodies by repertoire cloning. *J Cell Biochem*, 18D(Suppl):204, 1994.
16. Church A., **Siegel D.L.**: A desktop storage/retrieval system for historical reference serological cases. *Transfusion*, 34(Suppl):97S, 1994.
17. Church A., **Siegel D.L.**: Retrospective study of the microscopic evaluation of the antibody screen. *Transfusion*, 34(Suppl):19S, 1994.
18. Czerwinski M., **Siegel D.L.**, Spitalnik S.L.: Selected light chains combine with a given heavy chain to confer anti-N specificity. *Transfusion*, 35(Suppl):59S, 1995.
19. Herlyn D., Pereira S., Maruyama H., Van Belle P., Sivanandham M., Wallack M., Elder D., **Siegel D.L.**: Identification of tumor antigens using antibody phage display. (presented at the Sixth IBC Conference on Antibody Engineering, La Jolla, December 1995).
20. Herlyn D., Pereira S., Maruyama H., Van Belle P., Sivanandham M., Wallack M., Elder D., **Siegel D.L.**: Use of phage-expressed antibody cDNA libraries to identify new melanoma antigens. (presented at the IBC Conference on Immune Strategies for Cancer, San Diego, December 1995).
21. Herlyn D., Pereira S., Maruyama H., Jacob L., Van Belle P., Sivanandham M., Wallack M., Elder D., **Siegel D.L.**: Identification of tumor antigens using antibody phage display. (presented at Immunological Approaches to Tumor Therapy, University of Bonn, Germany, February 1996).

22. Herlyn D., Pereira S., Maruyama H., Jacob L., Van Belle P., Sivanandham M., Wallack M., Elder D., **Siegel D.L.**: Identification of tumor antigens with vaccine potential using antibody phage display. (presented at the annual meeting of the American Association for Cancer Research, 1996).
23. Czerwinski M., **Siegel D.L.**, Spitalnik S.L.: Selected light chains combine with a given heavy chain to confer anti-M or -N specificity. (presented at the Keystone Symposia on Molecular and Cellular Biology "Exploring and Exploiting Antibody and Ig Superfamily Combining Sites", Taos, March, 1996)
24. Wang L., Radic R.Z., **Siegel D.L.**, Galili U.: Characteristics of human anti-Gal genes. (presented at the Keystone Symposia on Molecular and Cellular Biology "Exploring and Exploiting Antibody and Ig Superfamily Combining Sites", Taos, March, 1996)
25. **Siegel D.L.**, Russell S., Chang T.: A plethora of human monoclonal anti-Rh antibodies isolated using phage display and magnetically-activated cell sorting. *Transfusion* 36:37, 1996 (Plenary Session abstract).
26. **Siegel D.L.**, Russell S., Chang T.: Highly-efficient isolation of cell surface-specific human monoclonal antibodies using phage display and magnetically-activated cell sorting. (presented at the Seventh IBC Conference on Antibody Engineering, La Jolla, December 1996).
27. Czerwinski M., **Siegel D.L.**, Spitalnik S.L.: Isolation of high affinity Fab fragments useful in blood group serology, *Transfusion* 37:89S, 1997.
28. Chang T.Y., **Siegel D.L.**: Isolation of a highly mutated human anti-B antibody from a phage-display library, *Transfusion* 37:89S, 1997.
29. **Siegel D.L.**, Chang T.Y.: Genetic and immunological properties of phage-displayed human anti-Rh(D) antibodies: Implications for Rh(D) epitope topology. (presented at the Eighth IBC Conference on Antibody Engineering, La Jolla, December 1997).
30. **Siegel D.L.**, Chang T.Y.: Genetic and immunological properties of phage-displayed human anti-Rh(D) antibodies: Implications for Rh(D) epitope topology, *Blood* 90:457a, 1997.
31. Chang T.Y., **Siegel D.L.**: Demonstrating Rh(D) antigenic relatedness using Fab/phage display and high sensitivity cell-based panning. (presented at the Third Annual International Conference on Display Technologies, San Francisco, June 1998).
32. Chang T.Y., **Siegel D.L.**: Epitope migration of anti-D antibodies, *Transfusion* 38:61S, 1998.
33. Roark JH, Chang T.Y., Caton M, **Siegel D.L.**: Isolation of human IgG platelet autoantibodies using phage display, *Transfusion* 38:1S, 1998 (Plenary Session abstract).
34. **Siegel D.L.**, Chang T.Y.: Epitope migration: Anti-Rh(D) antibodies as a model for human immunogenicity, *Blood* 92:671a, 1998.
35. Roark J.H., Chang T.Y., King S.M., Kacir S.E., Bussel J.B., Cines D.B., **Siegel D.L.**: Predominant expression of VH3-30 heavy chain genes in anti-platelet autoantibodies derived

from two patients with ITP. (presented at the FASEB summer conference, "Autoimmunity", Saxton River, Vermont, 1999).

36. **Siegel D.L.**, Reid M.E., Lee H., Blancher A.: Production of large repertoires of macaque mAbs to human RBCs using phage display, *Transfusion* 39:92S, 1999.
37. **Siegel, D.L.**: Understanding immunogenicity on a molecular level: New insights revealed by the Rh immune response, *Blood* 99:100a, 2001.
38. Westhoff C.M., Burd C., **Siegel D.L.**, Foskett J.K.: Evidence for both uptake and efflux of ammonium by Rh-associated glycoprotein (RhAG), *Blood* 100:223a, 2002.
39. Aqui N.A., Milone M.C., Sachs R., Stadtmauer E.A., Luger S., Shuster S., Porter D.L., Tsai D.E., Nasta S., Sachais B., O'Doherty U., **Siegel D.**, Sesok-Pizzini DA.: Comparison of clinical outcomes in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma undergoing autologous peripheral stem cell transplants, *Transfusion* 43:18A, 2003.
40. Aqui N.A., Milone M.C., Sachs R., Stadtmauer E.A., Luger S., Shuster S., Porter D.L., Tsai D.E., Nasta S., Sachais B., O'Doherty U., **Siegel D.**, Sesok-Pizzini DA.: Peripheral CD34 counts are predictive of outcome in leukapheresis in Hodgkin's disease and non-Hodgkin's lymphoma patients, *Transfusion* 43:43A, 2003.
41. Milone M., Magee D., Sachais B.S., **Siegel D.**, O'Doherty U., Sesok-Pizzini D.: Protocol to evaluate frequency of significant bacterial contamination of platelet products, *Transfusion* 43:169A, 2003.
42. **Siegel D.L.**, Loftus J.C., and McMillan R.: Characterization of an ITP patient-derived anti- $\alpha_{2b}\beta_3$ monoclonal antibody that inhibits platelet aggregation, *Blood* 102:87a, 2003.
43. **Siegel D.L.**: Phage display tools for automated blood typing, *Transfusion* 44:2a, 2004. (Plenary Session abstract)
44. Kasner M., Luger S., Stadtmauer E., Schuster S., Tsai D., Nasta S., Oerl A., Lore A., Goldstein S., Mangan P., Sachs R., **Siegel D.L.**, Porter D.: Utility of prophylactic autologous stem cell collection for patients with acute myeloid leukemia in first remission, *Blood* 104:1872a, 2004.
45. Ishii K., Payne A.S., Kacir S., Hanakawa Y., Li H., Lin C., **Siegel D.L.**, Stanley J.R. Pemphigus vulgaris human monoclonal antibodies cause dissociation of human keratinocytes. *J. Invest. Dermatol.* 124: A27, 2005.
46. Payne A.S., Ishii K., Kacir, S., Lin C., Li H., Hanakawa Y., Tsunoda K., Amagai M., **Siegel D.L.**, Stanley J.R.: Isolation and characterization of human monoclonal antibodies (mAbs) from a pemphigus vulgaris (PV) patient by phage display. *J. Invest. Dermatol* 124:A27, 2005.
47. **Siegel D.L.**: Lessons learned from idiopathic thrombocytopenic purpura (ITP). 66th Annual Meeting for Investigative Dermatology, Philadelphia, PA.
48. Ostertag E.M., Kacir S., Gulendran G., Ai J., Smith P., Zheng X.L., **Siegel D.L.**: Cloning inhibitory ADAMTS13 monoclonal autoantibodies from a TTP patient using phage display. *Transfusion* 45:1a, 2005. (Plenary Session abstract)

49. Olin R.L., Porter D.L., Luger S.M., Schuster S.J., Tsai D., Nasta S., Perl A., Loren A.W., Goldstein S., Glatstein E., **Siegel D.L.**, Vogl D.T., Mangan P., Cunningham K., Stadtmauer E.A.: Second autologous stem cell transplant (ASCT) as salvage therapy for relapsed multiple myeloma. *Blood* 106:342A, 2005.
50. Vogl D.T., Luger S., Porter D.L., Chong E.A., Schuster S.J. Tsai D.E., Perl A., Loren A., Goldstein S., Nasta S.D., Andreadis,C., Mangan P.A., Hummel K., **Siegel D.L.**, Glatstein E., Stadtmauer E.A.: Thalidomide and dexamethasone induction therapy is associated with superior progression-free survival after autotransplant for myeloma. *Blood* 106:342A, 2005.
51. Svoboda J., Elstrom R., Chong E.A., Andreadis C., Berkowitz A., Luger S.M., Porter D.L., Nasta S., Downs L.H., **Siegel D.L.**, Glatstein E., Alavi A., Stadtmauer E.A., Schuster S.J.: Prognostic value of FDG-PET in lymphoma patients undergoing autologous stem cell transplantation. *Blood* 106: 591A, 2005.
52. Payne A.S., **Siegel D.L.**, Stanley J.R.: Rational strategies for antibody targeted therapy in pemphigus vulgaris (PV). *J Invest Dermatol* 126: S6, 2006.
53. Ishii K., Li H., Lin C., Kacir S., Amagai M., **Siegel D.L.**, Stanley J.R.: Genetic restriction of anti-desmoglein (Dsg) 1 antibodies in pemphigus foliaceus (PF). *J Invest Dermatol* 126: S26, 2006.
54. Ostertag E.M., **Siegel D.L.**: Cloning of inhibitory ADAMTS13 monoclonal autoantibodies from a TTP patient using phage display and their use to create a mouse model of acquired ADAMTS13 deficiency. *J Clin. Apheresis*, 21:1-2, 2006. (Best Abstract Award)
55. **Siegel D.L.**, Ostertag E.M.: Inhibitory ADAMTS13 monoclonal autoantibodies cloned from TTP patients show restricted gene usage, inhibit murine ADAMTS13, and are blocked by rabbit anti-idiotypic antibodies. *Blood*, 108:31a, 2006.
56. Calcedo R., Vandenberghe L.H., Lin J., Gao G.-P., Limberis M., **Siegel D.**, Cleveland M., Auricchio A., Price M., Cleveland N., Steenssens L., Backhouse J., Moschou-Parara M., Wilson J.M.: Extensive AAV epidemiological study identifies a novel AAV variant with low seroprevalence. 10th Annual Meeting of the American Society of Gene Therapy, Seattle, WA, 2007.
57. Baliff J.P., Adamski J., Berkoski L., Eisenmann C., Milone M.C., O'Doherty U., Aqui N.A., Sachais B.S., **Siegel D.L.**: Low-density lipoprotein apheresis in an adolescent with a genetic form of steroid-resistant focal segmental glomerulosclerosis and familial combined hyperlipidemia. *J. Clin. Apheresis* 22:63, 2007 (presented at 28th Annual Meeting of the American Society for Apheresis, Nashville, TN).
58. Stanley J.R., Lin C., **Siegel D.L.**: Novel method for epidermal drug delivery with non-pathogenic monoclonal pemphigus antibodies,.68th Annual Meeting for the Society for Investigative Dermatology, Los Angeles, 2007.
59. Ishii K., **Siegel D.L.**, Stanley J.R.: Isolation of pathogenic pemphigus foliaceus (PF) monoclonal antibodies (mAbs) using an innovative phage display approach, "non-pathogenic epitope blocking". *J Invest Dermatol* 127: S10, 2007.

60. Stanley J.R., Lin C., **Siegel D.L.**: Novel method for epidermal drug delivery with non-pathogenic monoclonal pemphigus antibodies. *J Invest Dermatol* 127: S39, 2007.
61. Yamagami J., Ishii K., Payne A.S., Kacir S., Amagai M., **Siegel D.L.**, Stanley J.R.: Pathogenic pemphigus foliaceus (PF) and vulgaris (PV) antibodies share a consensus amino acid motif in their CDR3 regions. *J Invest Dermatol* 128: S7, 2008.
62. Yamagami J., Kacir S., Payne A.S., **Siegel D.L.**, Stanley J.R.: Tolerance to mature but not precursor desmoglein 1 (Dsg1) in non-pemphigus patients: implications for development of autoimmunity. *J Invest Dermatol* 129: S10, 2009.
63. Yamagami J., Payne A.S., Kacir S., Ishii K., **Siegel D.L.**, Stanley J.R.: Modifying the heavy chain third complementarity determining regions (H-CDR3) of pemphigus antibody to prevent pathogenicity but not binding suggests a novel approach to targeted therapy. *J Invest Dermatol*. 130: S17, 2010.
64. Yunk L., Ostertag E., Thiboutot M., Kacir S., Bdeir K., **Siegel D.L.**: Developing a mouse model for antibody-mediated thrombotic thrombocytopenic purpura using antibody phage display. 12th Annual Phage Display of Antibodies and Peptides, PEGS Protein Engineering Summit, Boston, MA, 2010.
65. Mangalmurti N.S., Friedman J.L., Wang L.C., Sun J., **Siegel D.L.**, Lee J.S., Albelda S.M.: Banked RBCs induce the expression of the receptor for advanced glycation endproducts (RAGE) on lung endothelial cells. American Thoracic Society International Conference, 2012.
66. Mangalmurti N.S., Friedman J.L., **Siegel D.L.**, Lee J.S., Albelda S.M.: Banked red cells induce Receptor for Advanced Glycation End products (RAGE) expression on lung endothelium and mediate vascular activation through RAGE. *Blood* 120:SCI-47, 2012.
67. Mangalmurti N.S., Qing D., **Siegel D.**, Lee J.S., Worthen G.S., Albelda S.M.: Transfusions modulate the host inflammatory response and prime the endothelium for subsequent injury through the receptor for advanced glycation end products. *Transfusion* 53:52a, 2013.
68. Azzato E., Carpenter H., Mischzanczuk M., Dinh L-H., DeMuth F., Magee D., Aqui N., **Siegel D.**, Sachais B.S.: Prospective monitoring of cryoprecipitate resulting in decreased product waste. *Transfusion* 53:232a, 2013.
69. Casina V., Wenbing H., Hanby H., **Siegel D.L.**, Mayne L., Englander S.W., Zheng X.L.: Deuterium-hydrogen exchange coupled with mass spectrometry revealed a novel autoantibody binding epitope and substrate recognition site in ADAMTS13 protease. *Blood* 122:455, 2013.
70. Garfall A.L., Dougherty A.L., Vogl D.T., Weiss B.W., Cohen A.D., Mangan P.A., O'Doherty U., **Siegel D.L.**, Porter D.L., Stadtmauer E.A.: Stem cell mobilization with Plerixafor + G-CSF in comparison to cyclophosphamide + G-CSF and time-to-progression after autologous stem cell transplantation for multiple myeloma. *Blood* 122:3354, 2013.
71. Azzato E., Gentile C., Carpenter H., **Siegel D.**, Watt C.: Successful red blood cell genotyping from leukoreduced packed red blood cell segments. 2014 Annual Meeting of the Association for Molecular Pathology, National Harbor, MD.

72. Gronwall C., Clancy R.M., Getu L., **Siegel D.L.**, Reed J.H., Buyon J., Silverman G.J.: Modulation of natural IgM-autoantibodies to oxidative stress-related neo-epitopes on apoptotic cells in newborns with mothers with anti-Ro autoimmunity. *Arthritis & Rheum.* 66:S584, 2014.
73. Bao J., Bdeir K., **Siegel D.L.**, Cines D.B., Zheng X.L.: Inhibition of ADAMTS13 activity by human neutrophil peptide 1 (NHP-1): Potential link between inflammation, onset of thrombotic thrombocytopenic purpura, and other thrombosis. *Blood* 124:599, 2014.
74. Casina V.C., Hu W., Hanby H.A., Pickens B., Mayne L., Ostertag E., Kacir S., **Siegel D.L.**, Englander S.W., Zheng X.L.: Autoantibody epitope mapping by hydrogen-deuterium exchange mass spectrometry at nearly single amino acid residue resolution reveals novel exosites on ADAMTS13 critical for substrate recognition and mechanism of autoimmune thrombotic thrombocytopenic purpura. *Blood* 124:108, 2014.
75. Villa C.H., Greineder C., Johnston I., Pan D., Carnemolla R., Cines D.B., Poncz M., **Siegel D.L.**, Muzykantov V.R.: Thrombomodulin fusion proteins coupled to human erythrocytes demonstrate anti-thrombotic and anti-inflammatory activity. *Blood* 126:3493, 2015.
76. Mei J., Qing D., Hotz M., **Siegel D.L.**, Sondheimer N., Mangalmurti N.S.: Mitochondrial DNA released following necroptosis accumulates on RBCs. American Thoracic Society Conference, 2016, San Francisco, CA.
77. Mangalmurti, N., Qing, D., Hotz, M., Siegel, D.L., Sondheimer, N., Mangalmurti, N.S. B97 mitochondria dysfunction in the development of lung disease: Mitochondrial DNA released following necroptosis accumulates on RBCs, *Amer. J. Resp. Crit. Care Med.* 193:1, 2016.
78. Bhoj V., Nunez-Cruz S., Feldman M.D., Mansfield K., Rader C., **Siegel D.L.**, Milone M.C.: Immunotherapy of medullary thyroid carcinoma by GDNF family receptor alpha 4 (GFR α 4)-targeted adoptive T cell immunotherapy. American Association for Cancer Research 2016 Annual Meeting, New Orleans, LA.
79. Tutwiler, V., Litvinov, R.I., Nagaswami, C., Russell, J.E., **Siegel, D.L.**, Villa, C.H., Pan, D., Muzykantov, V.R., Weisel, J.W. Erythrocyte rigidity affects blood clot contraction and formation of polyhedrocytes. *Blood* 128:3814, 2016.
80. Villa C.H., Pan D.C., Johnston I., Greineder C.F., Cines D.B., Poncz M., **Siegel D.L.**, Muzykantov V.: Coupling therapeutics to human erythrocytes demonstrates target-dependent effects on red cell physiology while preserving efficacy. *Blood* 128:701, 2016. (received 2016 ASH Abstract Achievement Award)
81. Fraietta J.A., Lacey S.F., Orlando E.J., Pruteanu-Malinici I., Gohil M., Lundh S., Boesteanu A.C., Wang Y., O'Connor R.S., Hwang W.-T., Pequignot E., Ambrose D.E., Zhang C., Wilcox N., Bedoya F., Dorfmeir C., Chen F., Tian L., Parakandi H., Gupta M., Young R.M., Johnson F.B., Kulikovskaya I., Liu L., Xu J., Kassim S.H., Suhoski-Davis M.M., Levine B.L., Frey N.V., **Siegel D.L.**, Huang A.C., Wherry E.J., Bitter H., Brogdon J.L., Porter D.L., June C.H., Melenhorst J.J. Identification of functional determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Blood* 130:3181, 2017.

82. Villa, C.H., Marcos-Contreras, O.A., Greineder, C.F., Hood, E., Shuvaeva, T., Walsh, L., Meyerson, J., Glassman, P., Brenner, J.S., **Siegel, D.L.**, Muzykantov, V.R. Red blood cell targeting of liposomes provides markedly enhanced circulation. Center for Targeted Therapeutics and Translation Nanomedicine Annual Symposium. 2017, University of Pennsylvania, Philadelphia, PA.
83. Hammers, C.M., Yuan, H., Lin, C., Tang, H.Y., **Siegel, D.L.**, Stanley, J.R. Cloning and analysis of bullous pemphigoid anti-BP180 IgG and IgE autoantibodies indicates predominance of VL1-47 gene usage and direct (from IgM) and indirect (through IgG) class switching to IgE. *Exp Dermatol* 27:E64-E65, 2018.
84. Dancy, E., Garfall, A.L., Cohen, A.D., Fraietta, J.A., Davis, M., Levine, B.L., **Siegel, D.L.**, Stadtmauer, E.A., Vogl, D.T., Waxman, A., Rapoport, A.P., Milone, M.D., June, C.H., Melenhorst, J.J. Clinical predictors of T cell fitness for CAR T cell manufacturing and efficacy in multiple myeloma. *Blood* 132:1886, 2018.
85. Gill, S.I., Vides, V., Frey, N.V., Metzger, S., O'Brien, M., Hexner, E., Mato, A.R., Lacey, S.F., Melenhorst, J.J., Pequignot, E., Gladney, W.L., Hwang, W-T, Lamontagne, A., Davis, M., Byrd, J.C., Schuster, S.J., **Siegel, D.L.**, Isaacs, R.E., June, C.H., Porter, D.L. Prospective clinical trial of anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia shows a high response rate. *Blood* 132:298, 2018.
86. Nobles, C.L., Everett, J.K., Reddy, S., Fraietta, J.A., Porter, D.L., Frey, N.V., Grupp, S.A., **Siegel, D.L.**, Lacey, S.F., June, C.H., Bushman, F.D., Melenhorst, J.J. Vector integration and efficacy of CD19-directed CAR T cell therapy in acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). *Blood* 132: 4548, 2018.
87. Chong, E.A., Levine, B.L., Grupp, S.A., Davis, M., **Siegel, D.L.**, Maude, S.L., Gladney, W.L., Frey, N.V., Porter, D.L., June, C.H., Schuster, S.J. CD19-directed CAR T-cell (CTL019) product viability and clinical outcomes in non-Hodgkin lymphomas and B-cell acute lymphoblastic leukemia. *Blood* 132: 197, 2018.
88. Melenhorst, J.J., Porter, D.L., Tian, L., Lacey, S.F., Nobles, C.L., Fraietta, J.A., Frey, N.V., Kulikovskaya, I., Gupta, M., Young, R.M., Ambrose, D.E., **Siegel, D.L.**, Bushman, F.D., June, C.H. Long-term remission of CLL sustained by pauciclonal anti-CD19 chimeric antigen receptor t (CTL019) cell clones. *Blood* 132:699, 2018.
89. Ohayon, Y., Corl, C.M., Leskowitz, R.M., Malykhin, A., Arostegui, S.M., Hennesy, N.A, Ngo, S., Levine, B.L., **Siegel, D.L.**, Fesnak, A., Davis, M.M. Robust automated cell counter and viability measurement for engineered T cell product release, *Cytotherapy* 20:S69, 2018.
90. Tebas P., Jadowsky, J., Shaw, P., Lee, G., Ando, D., Kim, S., Naing, S.Y., Lacey, S., Levine, B.L., **Siegel, D.L.**, June, C.H., Riley, J.L. Delayed viral rebound during ATI after infusion of CCR5 ZFN-treated CD4 T cells. 2019 Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington.
91. Gladney W.L., Leskowitz R., Dai A., McKee J., Gohil M., Xu J., Davis M., O'Rourke M., **Siegel D.**, Lacey S.F., Marshall A., Veloso E., Hwang W.-T., Hexner E., Porter D., Frey N., June C.H. A systematic approach to developing an allogeneic CAR T cell product. CAR-T and the rise of Cellicon Valley, Philadelphia, PA, 2019.

92. Gohill M., Dai A., Mackey S., Negorev D., Hennesy N., O'Rourke M., Lamontagne A., Holland D., Leskowitz R.M., Xu J., Ozerova M., McKee J.S., Pequignot E., **Siegel D.L.**, Schuster S., Svoboda J., Garfall A., Cohen A., Stadtmauer E., Gladney W., Levine B.L., June C., Fraietta J.A., Davis M.M. Myeloid derived suppressor cells (MDSCs) reduce the manufacturing feasibility of gene-edited T cells. 2019 Meeting of the International Society for Cellular Therapy, Melbourne, Australia.
93. Ozerova, M., Xu, J., Pequignot, E.C., McKee, J.S., Gohil, M., Haines, K., Lamontagne, A.M., **Siegel, D.L.**, Levine, B.L., Davis, M.M.: Evaluation of cryopreservation media formulation for collected leukapheresis products and for final manufactured T-cell products, 2019 ISCT Regional Meeting, Madison, WI.
94. Chong, E.A., Gerson, J.N., Landsburg, D.J., Nasta, S.D., Svoboda, J., Porter, D.L., Dengel, K., **Siegel, D.L.**, Gilmore, J., Barta, S., Levine, B.L., June, C.H., Schuster, S.J.: Outcomes in aggressive B-cell non-Hodgkin lymphomas with anti-CD19 CAR T-cell (CTL019) products not meeting commercial release specifications. 61st Annual Meeting of the American Society of Hematology, Orlando, FL (*Blood*, 134 Supplement 1:594, 2019).
95. Wang, M., Pruteanu, I., Cohen, A.D., Garfall, A.L., Milone M.C. , Tian, L., Gonzalez, V.E., Gill, S., Frey, N.V., Barrett, D.M., Ruella, M., Lacey, S.F., Svoboda, J., Chong, E.A., Fraietta, J.A., Davis, M., Nasta, S.D., Levine, B.L., **Siegel, D.L.**, Maude, S.L., Schuster, S.J., Stadtmauer, E.A., Grupp, S., Porter, D.L., June, C.H., Melenhorst, J.J.: Identification and validation of predictive biomarkers to CD19- and BCMA-specific CAR T-cell responses in CAR T-cell precursors. 61st Annual Meeting of the American Society of Hematology, Orlando, FL (*Blood*, 134 Supplement 1:622, 2019).
96. Garfall, A.L., Cohen, A.D., Lacey, S.F., Tian, L., Hwang, W.-T., Vogl, D.T., Waxman, A., Lancaster, E., Nelson, A.M., Ferthio, R., Fesnak, A., Lamontagne, A., Brennan, A., Williams, J., Gladney, W.L., Melenhorst, J.J., Young, R.M., **Siegel, D.L.**, Levine, B.L., Brogdon, J., Isaacs, R.E., June, C.H., Milone, M.C., Stadtmauer, E.A.: Combination anti-BCMA and anti-CD19 CAR T cells as consolidation of response to prior therapy in multiple myeloma. 61st Annual Meeting of the American Society of Hematology, Orlando, FL (*Blood*, 134 Supplement 1:1863, 2019).
97. Wang, M., Pruteanu, I., Cohen, A.D., Garfall, A.L., Tian, L., Lacey, S.F., Fraietta, J.A., Brogdon, J., Davis, M., Gonzalez, V.E., Levine, B.L., **Siegel, D.L.**, Milone, M.C., Stadtmauer, E.A., June, C.H., Melenhorst, J.J.: Response to Anti-BCMA CAR T cell therapy correlates with T cell exhaustion and activation status in T cells at baseline in myeloma. 61st Annual Meeting of the American Society of Hematology, Orlando, FL (*Blood*, 134 Supplement 1:1909, 2019).
98. Stadtmauer, E.A., Cohen, A.D., Weber, K., Lacey, S.F., Gonzalez V.E., Melenhorst, J.J., Fraietta, J.A., Plesa, G., Shea J., Matlawski, T., Cervini, A., Mangan, P., Gaymon A., Desjardin, S., Lancaster, E., Salas-Mckee J., Suhoski, M.M., Fesnak, A., O'Rourke M., Lamontagne A., **Siegel, D.L.**, Young, R.M., Chew, A., Nobles, C., Bushman, F.D., Chang, H.Y., Satpathy, A.T., Zhao, Y., Hwang, W.-T., Hexner, E.O., June, C.H.: First-in-human assessment of feasibility and safety of multiplexed genetic engineering of autologous T cells expressing NY-ESO -1 TCR and CRISPR/Cas9 gene edited to eliminate endogenous TCR and PD-1 (NYCE T cells) in advanced multiple myeloma (MM) and sarcoma. 61st Annual Meeting of the American Society of Hematology, Orlando, FL (*Blood*, 134 Supplement 1:49, 2019).

99. Gladney, W., Hexner, E., Salas-McKee, J., Fesnak, A., Jadowsky, J., Plesa, G., Leskowitz, R.M., Chew, A., Dai, A., Gohil, M., Xu, J., **Siegel, D.**, Lacey, S., Davis, M.M., June, C.: Pre-clinical development of multiplex-CRISPR-edited and gene therapy products. 2020 Meeting of the International Society for Cell & Gene Therapy, Paris Virtual (*Cytotherapy*, 22 Supplement S35, 2020).
100. Xu, J., Gohil, M., Stadtmauer, E., Fraietta, J.A., Gonzalez, V.E., Salas-McKee, J., Jadowsky, J., Gladney, W., Lamontagne, A., Fesnak, A., **Siegel, D.** Levine, B.L., Lacey, S., June, C., Davis, M.M.: Characterization of autologous T cells engineered to express NY-ESO-1 TCR with multiplexed CRISPR/Cas9 editing (NYCE T cells). 2020 Meeting of the International Society for Cell & Gene Therapy, Paris Virtual (*Cytotherapy*, 22 Supplement S35-36, 2020). (Best Abstract Award)
101. Lamontagne, A., Colligon, T.A., Taylor, C., Lewitt, L., Holland, D., Buchholz, K., Migliaccio, T., Brennan, A., Levine, B.L., Plesa, G., **Siegel, D.**: Maintaining excellence in a high volume academic cell therapy production facility through optimization of space utilization, operations, scheduling and staffing. 2020 Meeting of the International Society for Cell & Gene Therapy, Paris Virtual (*Cytotherapy*, 22 Supplement S149-150, 2020).
102. Xu, J., Pequignot, E., Holland, D., Lamontagne, A., **Siegel, D.**, Levine, B.L., M.M. Davis, M.M.: Predictive modeling demonstrating a two-factor signature as early as a week prior to harvest for chimeric antigen receptor (CAR) T cell manufacturing growth. 2020 Meeting of the International Society for Cell & Gene Therapy, Paris (virtual) (*Cytotherapy*, 22 Supplement S22, 2020).
103. Parvathaneni, K., **Siegel, D.L.**, Bhoj, V.G.: Engineered antigen-expressing CAAR-T cells targeting autoreactive B cells to ADAMTS13 in the context of thrombotic thrombocytopenic purpura. 23rd Annual Meeting of the American Society for Gene and Cell Therapy, 2020 (virtual) (*Molecular Therapy*, 28:410, 2020).
104. Uy, N.F., Pequignot, E., Frey, N.V., Davis, M., Hexner, E.O., Schuster, S.J., Gill, S., Loren, A.W., Grupp, S.A., Melenhorst, J.J., Lacey, S.F., Fraietta, J.A., Joan Gilmore, J., Lledo, L., Hwang, W.-T., **Siegel, D.L.**, Levine, B.L., June, C.H., Porter, D.L.: Hypogammaglobulinemia and infection risk in chronic lymphocytic leukemia (CLL) patients treated with CD19-directed chimeric antigen receptor T (CAR T) cells. 62st Annual Meeting of the American Society of Hematology, virtual (*Blood*, 136 Supplement 1:30, 2020).
105. Mason, N.J., Chester N., Xiong, A., Wu Y., Gulandan G., **Siegel, D.L.**: Development of a fully canine, anti-canine CTLA4 monoclonal antibody for comparative translational research. 2021 Center for Cellular Immunotherapies Research Retreat, University of Pennsylvania, Philadelphia, PA.
106. Gohil, M., Xu, J., Salas-McKee, J., Rojas Levine, J., Hasenmeyer, D., Eby, P., Dai, A., Mackey, S., Jain, A., Haines, K.M., Koterba, N., Kulikovskaya, I., Gupta, M., Chen, F., Gonzalez, V.E., Gabunia, K., Scholler, J., Young, R., **Siegel, D.L.**, Levine, B.L., Chew, A., June, C.H., Leskowitz, R.M., Lacey, S., Plesa, G., Davis, M.M.: Large-scale manufacture of CAR T cells engineered with augmented proliferative capacity and function via a 3 day process. 2021 Meeting of the International Society for Cell & Gene Therapy, New Orleans (virtual) (*Cytotherapy*, Supplement S23, 2021). (Best Abstract Award)

107. Hasenmayer, D., Lamontagne, A., Lewitt, L., Oner, S., Buchholz, K., Tran, K., Rojas Levine, J., Brennan, A.L., Fox, E., Ngo, S., McKenna, S., Plesa, G., **Siegel, D.L.**: Implementation of new cell washing technology in an academic cell therapy manufacturing laboratory. 2021 Meeting of the International Society for Cell & Gene Therapy, New Orleans (virtual) (*Cytotherapy*, Supplement S23, 2021).
108. Eby, P., Migliaccio, T., Haubein, N., Howell, J., Linnell, J., Buchholz, K., Colligon, T., Lamontagne, A., Lewitt, L., Ngo, S., Oner, S., Plesa, G., **Siegel, D.L.**: Implementation of a LabVantage-based laboratory inventory management system in a high-volume academic cell therapy production facility. 2021 Meeting of the International Society for Cell & Gene Therapy, New Orleans (virtual) (*Cytotherapy*, Supplement S23, 2021).
109. Brennan, A.L., Williams, J., Fox, E., Carreno, B., Linette, G., Levine, B.L., Plesa, G., **Siegel, D.L.**, Mackey, S., Fesnak, A.: Discussion of the requirements, challenges and processing adaptations involved in an academic technology transfer of neo-antigen peptide pulsed dendritic cells. 2021 Meeting of the International Society for Cell & Gene Therapy, New Orleans, LA (virtual) (*Cytotherapy*, Supplement S23, 2021).
110. Xu, J., Pequignot, E.C., Jain, A., Gohil, M., Alvarado, F., Sassoon, I., Fox, E., Holland, D., Dai, A., **Siegel, D.L.**, Levine, B.L., Jadowsky, J., Plesa, G., Davis, M.M.: Comparable stability of cryopreserved leukopheresis and investigational CAR T-cell clinical products formulated with in-house or commercial cryomedias. 2021 Meeting of the International Society for Cell & Gene Therapy, New Orleans (virtual) (*Cytotherapy*, Supplement S23, 2021).
111. Chen, R., Doshi, B.S., Nichols, T.C., Milone, M.C., Samelson-Jones, B.J., Arruda, V.R., Bhoj, V., **Siegel, D.L.**: Ontogeny of the alloimmune anti-canine Factor VIII inhibitor response in severe hemophilia A dogs. 63rd Annual Meeting of the American Society of Hematology, Atlanta, GA (*Blood*, 138 Supplement 1:3173, 2021).
112. Melenhorst, J.J., Chen G.M., Wang, M., Porter, D.L., Gao P., Bandyopadhyay S., Pruteanu-Malinici, J., Nobles, C.L., Maji, S., Frey, N.V., Gill, S., Tian, L., Kulikovskaya I., Davis, M.M., Fraietta, J.A., Brogdon, J.L., Young, R., Ambrose, D.E., Chew, A., Levine, B.L., **Siegel, D.L.**, Alanio, C., Wherry, E.J., Bushman, F.D., Lacey, S.F., Tan, K., June, C.H: Decade-long remissions of leukemia sustained by the persistence of activated CD4+ CAR T cells. 63rd Annual Meeting of the American Society of Hematology, Atlanta, GA (*Blood*, 138 Supplement 1:166, 2021).
113. Russell, A.L., Pequignot, E., Xu, J., Gohil, M., Haines, K.M., Jain, A., Alvarado, F., Sporici, K., Holland, D., Karar, J., Jadowsky, J., Plesa, G., **Siegel, D.**, Levine, B.L., Plesa, G., Davis, M.M.: Evaluation of commercial cryomeia formulations for leukapheresis starting material and final T-cell therapeutic products. 2022 Meeting of the International Society for Cell & Gene Therapy, San Francisco, CA (*Cytotherapy*, Supplement S24, 2022).
114. Oner, B., O'Neil, Z., Howell, J., Linnell, J., Haubein, N., Lewitt, L., Eby, P., Mackey, S., McKenna, S., Ngo, S., Colligori, T.A., Dai, A., Brennan, A.L., Plesa, G., **Siegel, D.**: Phased approach to design and implementation of LabVantage hosted electronic sample tracker platform. 2022 Meeting of the International Society for Cell & Gene Therapy, San Francisco, CA (*Cytotherapy*, Supplement S24, 2022).

115. Gohil, M., Hassenmayer, D., Haines, K.M., Jain, A., Lewitt, L., Sporici, K., Dai, A., Negorev, D., Gonzalez, V.E., Kulikovskava, I., Reynolds, R., Migliaccio, T., Brennan, A.L., Colligan, T.A., Russell, A.L., Wang, Z., June, C., **Siegel, D.**, Levine, B.L., Fraietta, J.A., Jadowsky, J., Plesa, G., Davis, M.M.: Supply chain crisis story: Culture bag shortage enforced validation of an alternative expansion system for CAR-T cells. 2022 Meeting of the International Society for Cell & Gene Therapy, San Francisco, CA (*Cytotherapy*, Supplement S24, 2022).
116. Meng, C., Halkidis, K., Liu, S., **Siegel, D.L.** Zheng, X.L.: The mechanism of antibody-mediated inhibition of ADAMTS13 in immune thrombotic thrombocytopenic purpura. 64th Annual Meeting of the American Society of Hematology, New Orleans, LA (*Blood*, 140 Supplement 1:5527-5528, 2022).
117. Plesa, G., Brennan, A., Rojas Levine, J., Hasenmayer, D., Buchholz, K., Migliaccio, T., Holland, D., Colligan, T., Mackey, S., Dai, A., Petrella, J., Ngo, S., Fesnak, A., Davis, M.M., **Siegel, D.**: Multiple efficiencies gained by implementing a significantly shorter manufacturing schedule for production of CAR T cell products. 2023 Meeting of the International Society for Cell & Gene Therapy, Paris, FR (*Cytotherapy*, Supplement S25, 2023).
118. Petrella, J., Dai, A., Mackey, S., Ngo, S., Correa, A., Brennan, A., Colligan, T., Tran, K., Buchholz, K., Fesnak, A., Plesa, G., **Siegel, D.**: Development and feasibility of release assays to test for CD33-Knockout efficiency and potency of gene-modified CD34+ HSCs for large-scale manufactured products. 2023 Meeting of the International Society for Cell & Gene Therapy, Paris, FR (*Cytotherapy*, Supplement S25, 2023).
119. Mackey, S., Dai, A., Gong, N., McGettigan, B., Jefferson, P., Petrella, J., Gohil, M., Fesnak, A., **Siegel, D.**, Davis, M.M., Gabriela Plesa, G.: Developing and optimizing multicolor flow cytometry methods for the manufacture and release of 3-day huCART products. 2023 Meeting of the International Society for Cell & Gene Therapy, Paris, FR (*Cytotherapy*, Supplement S25, 2023).
120. Barber-Rotenberg, J.S., Leskowitz, R.M., Jadowsky, J., Hexner, E., Binder, Z.A., Bhoj, V.G., **Siegel, D.**, Fraietta, J.A., O'Rourke, D., Levine, B.L., Chew, A., June, C.: FDA cytotoxicity and potency review: Opportunities for assay clarity. 2023 Meeting of the International Society for Cell & Gene Therapy, Paris, FR (*Cytotherapy*, Supplement S25, 2023).
121. Gohil, M., Jain, A., Lee, K., Pequignot, E., Mackey, S., Trivedi, H., Sporici, K., Russell, A.L., Dai, A., Petralla, J., Hebbal, S., Gonzalez, V.E., Kulikovskava, I., Brennan, A.L., Svoboda, J., Levine, B.L., June, C., **Siegel, D.**, Fraietta, J.A., Plesa, G., Davis, M.M.: CAR-T cell manufacturing (MFG) in a 2ML microbioreactor. 2023 Meeting of the International Society for Cell & Gene Therapy, Paris, FR (*Cytotherapy*, Supplement S25, 2023).
122. Svoboda, J., Landsburg, D.L., Chong, E.A., Barta, S.K., Nasta, S.D., Ruella, M., Hexner, E.O., Marshall, A., Leskowitz, R., Four, M., Shea, J., Cervini, A., Davis, M.M., Plesa, G., Hasenmayer, D., Amortegui, J.R., Hwang, W., Frey, N., **Siegel, D.L.**, Fraietta, J., Levine, B., Porter, D.L., Schuster, S.J., June, C.H.: Fourth generation huCART19-IL18 produces durable responses in lymphoma patients previously relapsed/refractory to anti-CD19 CAR T-cell therapy. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland (*Hematological Oncology*, 41: Suppl 2, S37, 2023).

123. Mack, E.A., Dougher, M.C., Cahill, C., Murter, M., Schell, K., Tanhehco, Y., **Siegel, D.L.**, Fesnak, A., Vijay Bhoj, V., Kambayashi, T., Aqui, N., O'Doherty, U.: Red cell exchange for rapid leukoreduction for adults hyperleukocytosis and leukostasis. 2023 Annual Meeting of the AABB, Nashville, TN.
124. **Siegel, D.L.**, Gulendran, G., Xiong, A., Yoshimoto, S., Chester, N., Wang, H., Brillantes, M., Pusey, A., Sax, A., Mason, N.: Developing canine immunotherapies to fully leverage comparative oncology and inform human clinical trials. 2023 Annual Meeting of the AABB, Nashville, TN (*Blood 142 Supplement 1: 217*)
125. Bhagwat, A.S., Torres, L., Shestova, O., Shestov, M., Frey, N.N., Hexner, E.O., Luger, S.M., Loren, A.W., Martin, M.E., McCurdy, S.R., Perl, A., Stadtmauer, E.A., Mangan, J.K., Brogdon, J., Fraietta, J.A., Hwang, W.-T., **Siegel, D.L.**, Kenderian, S.S., Porter, D.L., June, C., Gill, S.: Cytokine release syndrome results in reduced AML killing by CD123 CAR T cells. 2023 Meeting of the American Society for Hematology, San Diego, CA.
126. Mackey, S., Dai, A., Davis, Fesnak, A., **Siegel, D.L.**, Plesa, G.: Flow cytometry case studies illustrating comprehensive approach required for developing, optimizing, and implementing, multicolor panels for the manufacturing and release of investigational cell therapy products at UPenn. 2024 Meeting of the International Society for Cell & Gene Therapy, Vancouver, CA (*Cytotherapy*, Supplement 26: S137-S138, 2024).
127. Jain, A., Amses, K., Markovska, M., Haines, K.M., Gohil, M., Pequignot, E., Sporic, K., Uhera, Y., Trivedi, H., Brennan, A.L., Plesa, G., Young, R., June, C., Sherrill-Mix, S.A., Everett, J.K., **Siegel, D.L.**, Bushman, F.D., Fraietta, J.A., Weber, E.W., David, M.M.: Harnessing potent naïve like T cells for precision CAR T manufacturing. 2024 Meeting of the International Society for Cell & Gene Therapy, Vancouver, CA (*Cytotherapy*, Supplement 26: S135, 2024).
128. Khadka, R.H., Parvathaneni, K., Hresko, M., Zhao, H., Tezer, E., Hoffman, J., **Siegel, D.L.**, Bhoj, V.G. ADAMTS13-chimeric auto-antigen receptor T cells to target autoreactive B cells as a treatment for immune-mediated thrombotic thrombocytopenic purpura. 2024 Annual Meeting of the AABB, Houston, TX. (*Plenary Abstract*)
129. **Siegel, D.L.**, Najrana, T., Guilfoyle, R., Pond-Tor, S., Kurtis, J.D. VHH-IgG mAbs targeting PfGBP130 inhibit *Plasmodium falciparum* growth *in vitro*. 2024 Annual Meeting of the American Society of Tropical Medicine & Hygiene, New Orleans, LA.
130. Hopkins, C.R., DiNofia, A.M., Maude, S.L., Chen, G.M., Boateng-Antwi, K.A.M., Perazzelli, J., Mendez Corea A.F., Shestov, A., Gohil, M., Li, Y., Hwang, W.-T., Valenti, B., Christensen, S., Jadowsky, J., Myers, R.M., Diorio, C., Davis, M.M., Colligon, T., Plesa G., **Siegel, D.L.**, Bruce Levine, B., June, C.H., O'Connor, R.S., Grupp, S.A., Fraietta, J.A.: In vivo persistence and function of CAR19 T-cell products for pediatric B-cell acute lymphoblastic leukemia are impacted by media, cytokine supplementation and metabolite bioavailability during ex vivo manufacturing. 2024 Annual Meeting of the American Society for Hematology, San Diego, CA.
131. Song, A.T., Deshmukh, M., Song, D.C., Fan, T.-J., Gabunia, K., Ji, V.M., **Siegel, D.L.***, Scholler, J.*, June, C.H.* (*senior co-authors) Functional screening for a novel CAR scFv targeting mesothelin, 2025 27th Annual Meeting of the Translational Research Cancer Centers Consortium (TRCC), Seven Springs Mountain Resort, Champion, PA.

132. Tassoni, A.L., Petrella, J., Dai, A., Yaghnani, M., Buchholz, K., Plesa, G., **Siegel, D.L.** Model for framework to determine alert- and action-level limits for nonviable particulate sampling performed during routine environmental monitoring, Cellicon Valley '25: The Future of Cell and Gene Therapies, Philadelphia, PA.
133. McGettigan-Croce, B., Petrella, J., Dai, A., Mackey, S., Tran, K., McKenna, S., Brennan, A.L., Colligon, T.A., Buchholz, K., Levine, B.L., **Siegel, D.L.**, Plesa, G. Implementation of rapid mycoplasma testing to accelerate the release of cell and gene therapy products, 2025 Annual Meeting of the International Society for Cell & Gene Therapy, New Orleans, LA.
134. Petrella, J., Dai, A., Mackey, S., Correa, A., Brennan, A., Fesnak, A., **Siegel, D.L.**, Plesa, G. Feasibility of releasing fresh CAR T cell products for infusion based on studying product post-harvest stability, 2025 Annual Meeting of the International Society for Cell & Gene Therapy, New Orleans, LA.
135. Blair, M., Yucel, N., Stanley, W., Truong, T., Xu, J., Milone, M.C., **Siegel, D.L.**, Johnson, L.A. SynKIR-310 provides a novel split-signal CAR T platform (KIR-CAR) based upon Natural Killer cell signaling to prolong anti-tumor treatment in patients with B-NHL, 28th Annual Meeting of the American Society of Cell & Gene Therapy, New Orleans, LA.
136. Hopkins, C.R., DiNofia, A.M., Maude, S.L., Chen, G., Lavorando, M., Boateng-Antwi, K.A., Bartoszek, R., Perazzelli, J., Mendez Corea A.F., Shestov, A., Gohil, M., Li, Y., Hwang, W.-T., Valenti, B., Christensen, S., Jadowsky, J., Myers, R.M., Diorio, C., Davis, M.M., Colligon, T., Plesa, G., **Siegel, D.L.**, Bruce Levine, B., June, C.H., O'Connor, R.S., Grupp, S.A., Fraietta, J.A.: In vivo persistence and function of CAR19 T-cell products for pediatric B-cell acute lymphoblastic leukemia are impacted by media, cytokine, and metabolite bioavailability during ex vivo expansion. 28th Annual Meeting of the American Society of Cell & Gene Therapy, New Orleans, LA.
137. Tanyi, J.L., Haas, A.R., O'Hara, M.A., Altan, M., Gahvari, Z.J., Al-Rajabi, R., **Siegel, D.L.**, Serman, D.H., Milone, M.C., Howard, S.K., Winters, E.A., Campanile, A., Xu, J., Johnson, L.A. SynKIR-CAR T cell Advanced Research (STAR)-101 Phase 1 clinical trial for patients with advanced mesothelin-expressing ovarian cancer, mesothelioma, or cholangiocarcinoma, 2025 American Society of Clinical Oncology, Chicago, IL.

Editorials, Reviews, Chapters, Committee Reports:

1. **Siegel D.L.:** Chromaffin cell synapsin? *Nature* 327:467-468, 1987.
2. Branton D., **Siegel D.L.:** Electron microscopy of red cell cytoskeletal proteins. in Shohet, S.B. and Mohandas, N. (Eds.) Methods in Hematology, Volume 19, Churchill-Livingston, New York, 1988.
3. **Siegel D.L.**, Silberstein L.E.: Acquired hemolytic anemia. In Conn, R.B. (Ed.) Current Diagnosis 8, W.B. Saunders Co., Philadelphia, 1990.
4. **Siegel D.L.**, Silberstein L.E.: Red cell antigen specificities and autoimmune hemolytic anemias. In Agre, P. and Cartron, J.P. (Eds.) Protein Blood Group Antigens of the Human Red Cell: Structure, Function, and Clinical Significance, Johns Hopkins University Press, Baltimore, 1992.

5. **Siegel D.L.** and Silberstein L.E.: Structural analyses of red blood cell autoantibodies. In Garratty, G. (Ed.) Immunobiology of Transfusion Medicine, Marcel Dekker, New York, 1994.
6. **Siegel D.L.** and Silberstein L.E.: Red blood cell autoantibodies. In Ness P. and Anderson K. (Eds.), Scientific Basis of Transfusion Medicine: Implications for Clinical Practice, W.B. Saunders Co., Philadelphia, 1994.
7. **Siegel D.L.**: New Approaches to Monoclonal Antibody Production. In Garratty G. (Ed.), Applications of Molecular Biology to Blood Transfusion Medicine, American Association of Blood Banks, Bethesda, 1997, 73-102.
8. **Siegel D.L.** Mechanism of Rh immune globulin prophylaxis revisited. In The Compendium 1999, American Association of Blood Banks, Bethesda, 1999, 160-163.
9. Hug B., **Siegel D.L.** and Silberstein L.E.: Red blood cell autoantibodies. In Anderson K and Ness P. (Eds.), Scientific Basis of Transfusion Medicine: Implications for Clinical Practice, 2nd edition, W.B. Saunders Co., Philadelphia, 2000.
10. Thurer R.L., Luban N.L.C., AuBuchon J.P., Silver H., McCarthy L.J., Dzik S, Stowell C.P., Moore S.B., Vamvakas E.C., Armstrong W., Kanter M.H., Jeter E., Becker J., Higgins M., Galel S., Kleinman S., Marshall C.S., Newman R. Ocariz J.A., Blackall D., Petz L.D., Toy P., Oberman H., **Siegel D.L.**, T.H. Price, Slichter S.J., Gernsheimer T., Mintz P., Goodnough L.T., Lipford E.H., and Simpson M.B. Universal WBC reduction, *Transfusion* 40:751-752, 2000.
11. Chang T.Y. and **Siegel D.L.** The limitations of site-directed mutagenesis in the localization of Rh D epitopes, *Blood* 96:1196-1199, 2000.
12. **Siegel D.L.** Application of molecular biology in the engineering of IV immunoglobulins. In Smit-Sibinga C. Th. (Ed.), Molecular Biology in Blood Transfusion, Kluwer Academic Publishers, Boston, 2000, pp. 211-223.
13. **Siegel D.L.** What's a clinically significant antibody? In The Compendium 2000, American Association of Blood Banks, Bethesda, 2000, 120-125.
14. **Siegel D.L.**: Cell-surface panning of phage-display libraries. In Barbas C.F., Burton, D.R., Scott J.K. and Silverman G.J. (Eds.), Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001, pp. 23.1-23.32.
15. **Siegel D.L.** Research and clinical applications of antibody phage display in transfusion medicine. *Transfusion Medicine Reviews* 15:35-52, 2001.
16. **Siegel D.L.** What's a clinically significant antibody? In The Compendium 2001, American Association of Blood Banks, Bethesda, 2001, 115-120.
17. **Siegel D.L.** Pre-transfusion compatibility testing. In Hillyer C.D., Hillyer K.L., Strobl F.J., Jefferies L.C., and Silberstein L.E. (Eds.), Handbook of Transfusion Medicine, Academic Press, San Diego, 2002, 107-114.

18. **Siegel D.L.** Selecting immunoglobulins to cell-surface antigens using magnetic sorting techniques. in Aitken, R. and O'Brien, P.M. (Eds.) Methods in Molecular Biology vol 178: Antibody Phage Display: Methods and Protocols, Humana Press, Totowa, NJ, 2002, 219-226.
19. Westhoff C., **Siegel D.L.** Rh and LW blood group systems. In Simon T.L., Dzik W.H., Snyder E.L., Stowell C.P, and Strauss R.G. (Eds.), Rossi's Principles of Transfusion Medicine, 3rd edition, Lippincott Williams & Wilkins, Philadelphia, 2002, 113-122.
20. **Siegel D.L.** Recombinant monoclonal antibody technology. *Transfusion Clinique et Biologique* 9:15-22, 2002.
21. **Siegel, D.L.**, Czerwinski M, Spitalnik S.L. Structural/genetic analysis of monoclonal antibodies to blood group antigens. *Transfusion Clinique et Biologique* 9:83-97, 2002.
22. **Siegel D.L.** Diagnostic and therapeutic applications of phage display technology. In Stowell C.P. and Dzik W.H. (Eds.), Emerging Technologies and Therapies in Transfusion Medicine, American Association of Blood Banks, Bethesda, 2003.
23. Cines D.B., McKenzie S.E., **Siegel D.L.** Mechanisms of action of therapeutics in idiopathic thrombocytopenic purpura. *Journal of Pediatric Hematology/Oncology* 25: S52-56, 2003.
24. **Siegel D.L.:** Developing phage display tools for use in Transfusion Medicine. *Transfusion* 45:100S-108S, 2005.
25. **Siegel D.L.:** Phage-display tools for blood typing. *Current Hematology Reports* 4:459-464, 2005.
26. Klumpp T.T., **Siegel D.L.:** Transfusion Medicine. In Kahn, M. (ed.) American Society for Hematology Self-Assessment Program, 3rd edition, Chapter 16, 2006.
27. **Siegel D.L.:** Phage display-based molecular methods in immunohematology. *Transfusion* 47:89S-94S, 2007.
28. **Siegel D.L.:** Translational applications of antibody phage display. *Immunologic Research* 42:118-131, 2008.
29. Westhoff C., **Siegel D.L.:** Rh and LW blood group systems. In Simon T.L., Snyder E.L., Stowell C.P., Strauss R.G. (Eds.), Rossi's Principles of Transfusion Medicine, 4th edition, Wiley-Blackwell, NY, 2009.
30. **Siegel D.L.**, Quillen K.: Transfusion Medicine. In Gregory S.A. and McCrae K.R. (eds.) American Society for Hematology Self-Assessment Program, 4th edition, Chapter 11, 2010.
31. **Siegel D.L.:** Clinical applications of phage display-derived peptides and proteins. In Hyman P., Abedon S. (eds) Bacteriophages in Health and Disease, CABI Press, Cambridge, U.K., 2012.
32. Cines D.B., McCrae K.R., Zheng X.L., Sachais B.S., Luning Prak E., **Siegel D.L.:** Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders. *Blood* 120:4134-4142, 2012.

33. **Siegel D.L.**: Transfusion reactions. In Kellum J.A., Fortenberry J.D., Fuchs, B.D. and Shaw A. (eds.) *Clinical Decision Support: Critical Care Medicine, Decision Support in Medicine*, LLC, Wilmington, DE, 2013.
34. O'Doherty U., **Siegel D.L.**: Transfusion reactions. In Lancken, P.N., Manaker S., Kohl B.A., Hanson C.W. (eds) *The Intensive Care Unit Manual*, 2nd edition, Elsevier Saunders, Philadelphia, 2014.
35. Villa C.H., Pan D.C., Zaitsev S., Cines D.B., **Siegel D.L.**, Muzykantov, V.R. Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier. *Therapeutic Delivery* 6:795-826, 2015.
36. Zhao A., Tohidkia M.R., **Siegel D.L.**, Coukos G., Omid Y.: Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy. *Critical Reviews in Biotechnology* 36:276-289, 2016.
37. Westhoff C., **Siegel D.L.** Rh and LW Blood Groups. In Simon T.L., McCullough J., Snyder E.L., Solheim B.G., Strauss R.G. (Eds.), Rossi's Principles of Transfusion Medicine, 5th edition, Wiley, NY, 2016.
38. Fesnak, A., Chie, Y.L., **Siegel, D.L.**, Maus, M.V. CAR-T cell therapies from the transfusion medicine perspective. *Transfusion Medicine Reviews* 30:139-145, 2016.
39. Villa C.H., Cines D.B., **Siegel D.L.**, Muzykantov V.R. Erythrocytes as carriers for drug delivery in blood transfusion and beyond. *Transfusion Medicine Reviews* 31:26-35, 2017.
40. Floch, A., **Siegel D.L.**, Westhoff, C.M. Rh and LW Blood Groups. In Simon T.L., McCullough J., Snyder E.L., Roback, J.D., Gehrie, E. (Eds.), Rossi's Principles of Transfusion Medicine, 6th edition, Wiley, NY, 2021.
41. Glassman, P.M., Hood, E.D., Ferguson, L.T., Zhao Z., **Don L. Siegel, D.L.**, Mitragotri, S., Brenner, J.S., Muzykantov, V.R.: Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers. *Advanced Drug Deliveries Reviews* 178:113992, 2021.
42. Fesnak, A.F., **Siegel D.L.** CAR-T cells and other cellular immunotherapies. In Simon T.L., McCullough J., Snyder E.L., Roback, J.D., Gehrie, E. (Eds.), Rossi's Principles of Transfusion Medicine, 6th edition, Wiley, NY, 2022.
43. Holmberg, J.A., Henry, S.M., Burnouf, T., Devine, D., Marschner, S., Boothby, T.C., Burger, S.R., Chou, S.T., Custer, B., Blumberg, N., **Siegel, D.L.**, Spitalnik, S.L.: National Blood Foundation 2021 Research and Development Summit: Discovery, innovation, and challenges in advancing blood and biotherapies. *Transfusion* 62:2391-2404, 2022.
44. Bloch, E.M., Triulzi, D., Sachais, B.S., Hod, E.A., Cushing, M., Jacobs, J.W., Tobian, A.A.R., Shan, H., Leonard N. Chen, L.N., McGonigle, A.M., Tormey, C.A., Szczepiorkowski, Z.M., **Siegel, D.L.**: The incompatible match for transfusion medicine fellowships. *Transfusion*, 65:246-248, 2025.

Alternative Media:

- Live telephone interview discussing new approaches for preventing and treating hemolytic disease of the newborn, "Health and Fitness Show with Ellen Ratner," WCHF radio (AM 1390), Washington, DC., April, 1997.
- "Phage-Displayed Antibodies for Diagnosis and Therapy," American Science Update (video), Science Technology Network, NY, June 1997.
- "Making Strides in the Laboratory," Main Line Today (edited by Jennifer Valerio), July 1998.
- "Phage Display: A New Technology for Producing Recombinant Human Antibodies for Rh Blood Typing," American Society for Clinical Pathology (ASCP) Teleconference, April 1999.
- "LDL-Apheresis for Hyperlipidemic Disorders", ABC News, June 2004.
- "Firm to Automate Typing of Blood", Philadelphia Business Journal, February, 2004.
- "Chilean Teen Gets Life-Saving Treatment at Penn", WPVI Health News, December, 2006.
- "Cellular Vaccine Development as Cancer Therapy", ReachMD Sirius/XM Radio 160, May, 2009.
- "The Evolving Role of Apheresis in Cellular Therapies", Highlights of the 2011 ASFA Meeting, Webinar, October, 2011.
- "The Expanding Role of Transfusion Medicine in Personalized Medicine and Therapeutics", in "Ortho On-Demand Webinar series: Transfusion Medicine -- What's New and What's Next", October, 2012.
- "CAR T-Cell Therapies: Changing the Paradigm in Cancer Treatment", in AABB News, November/December 2017.
- "The War on Cancer: On the front line", Philadelphia Business Journal, February, 2018.
- "From Research to Manufacturing to Treatment: A One-Stop CAR-T Shop", in Cell Therapy, December, 2018.
- "Cellular Therapies for Cancer", Seeking Solutions with Suzanne, Comcast Television Network, November, 2019.
- "How One NBF Grant Recipient Proliferated His Success in Many Different Aspects of His Career", NBF: Shaping the Industry, AABB News, March, 2020.
- "Your Guide to Donating Blood During Coronavirus – And After", Shape Magazine, May 11, 2020.
- "Controversial Uses of Blood Components", AABB News, May, 2020.
- "Transfusion Medicine Meets Cell & Gene Therapy: ISCT Featured Member: Don L. Siegel, Ph.D., M.D." ISCT Telegraft, June, 2020.

“Enrolling Now: A CAR-T Trial for Medullary Thyroid Cancer”, Penn Medicine Podcast, first-
aired February 10, 2022.

“Workforce Issues in Transfusion Medicine: Cellular Therapy Technical Staff”, AABB, webinar,
first aired February 2023.

“CAR T-Cell Therapy for Medullary Thyroid Cancer: The Personal Story that Inspired the Science”,
Genetic Engineering and Biotechnology News, webinar, first aired June 2023.

“Thrombotic Thrombocytopenic Purpura (TTP): A Multidisciplinary Team Approach”, VuMedi
Video Education Platform for Physicians, first aired July 2024.

Patents:

1. **Siegel D.L.:** Amphipathic Microcarriers. United States Patent Office #4,415,668, issued 11/15/83.
2. **Siegel D.L.:** Composition and Methods for Detection of Antibody Binding to Cells. Australian Patent Office #732758, issued 10/10/97.
3. **Siegel D.L.:** Magnetically Activated Cell Sorting for Production of Proteins. United States Patent Office #5,876,925, issued 3/2/99.
4. **Siegel D.L.:** Composition and Methods for Detection of Antibody Binding to Cells-I. United States Patent Office #5,985,543, issued 11/16/99.
5. **Siegel D.L.:** Panning Phage Display Libraries. Australian Patent Office #722978, issued 11/30/00.
6. **Siegel D.L.:** Rh(D)-Binding Proteins and Magnetically Activated Cell Sorting Method for Production Thereof. United States Patent Office #6,255,455, issued 7/3/01.
7. **Siegel D.L.:** Method of Agglutinating Cells. European PCT application filed in 9 countries, patent number EP0935754, issued 10/7/04.
8. **Siegel D.L.:** Rh(D)-Binding Proteins and Magnetically Activated Cell Sorting Method for Production Thereof. United States Patent Office #6,858,719 B2, issued 2/22/05.
9. **Siegel D.L.:** Composition and Methods for Detection of Antibody Binding to Cells. United States Patent Office # 6,979,534 B1, issued 12/27/05.
10. **Siegel D.L.:** Magnetically Activated Cell Sorting for Production of Proteins. Canadian Patent Office #2,268,397, issued 6/8/07.
11. **Siegel D.L.:** Compositions, Methods, and Kits for Detection of an Antigen on a Cell and in a Biological Mixture, European Patent Office granted, #03754675.1-2403, 2008.
12. **Siegel D.L.:** Compositions, Methods, and Kits for Detection of an Antigen on a Cell and in a Biological Mixture, granted Hong Kong, #HK1077851, 2008.

13. **Siegel D.L.:** Compositions, Methods, and Kits for Detection of an Antigen on a Cell and in a Biological Mixture, granted Australia, #200327291, 2008.
14. **Siegel D.L.:** Compositions, Methods, and Kits for Detection of an Antigen on a Cell and in a Biological Mixture, granted Mexico, #PA/a/2005/002934, 2008.
15. **Siegel D.L.:** Magnetically Activated Cell Sorting for Production of Proteins. Japanese Patent Office #4101298, issued 3/28/08.
16. **Siegel D.L.:** Composition and Methods for Detection of Antibody Binding to Cells. Canadian Patent Office #2,268,339, issued 6/2/2009.
17. **Siegel D.L.:** Compositions, Methods, and Kits Relating to Anti-Platelet Autoantibodies and Inhibitors Thereof. Australian Patent Office #2003251791, issued 6/26/2009.
18. **Siegel D.L.:** Compositions, Methods, and Kits for Detection of an Antigen on a Cell and in a Biological Mixture, granted Japan, #4601427, 2010.
19. **Siegel D.L.:** Compositions and Methods for Detection of Antibody Binding to Cells. United States Patent Office #7,709,219 B2, issued May 4, 2010.
20. **Siegel D.L.:** Compositions, Methods and Kits Relating to Anti-Platelet Autoantibodies and Inhibitors Thereof. Japanese Patent Office, #4660189, 1/7/2011.
21. **Siegel D.L.:** Rh(D)-binding Proteins. United States Patent Office #8,124,742, issued February 28, 2012.
22. **Siegel D.L.:** Compositions, Methods, and Kits Relating to Anti-Platelet Autoantibodies and Inhibitors Thereof. United States Patent Office #8,216,581, issued July 10, 2012.
23. Payne A.S., **Siegel D.L.**, Stanley J.R.: Anti-Autoimmune Antibodies for Treatment of Pemphigus. United States Patent Office, #8,298,545 B2, issued October 30, 2012.
24. Stanley J.R., Amagai M., **Siegel D.L.:** Drug Delivery to Human Tissues by Single Chain Variable Region Antibody Fragments Cloned by Phage Display. United States Patent Office, #8,470,323 B2, issued June 25, 2013.
25. **Siegel D.L.:** Compositions, Methods, and Kits for Detection of an Antigen on a Cell and in a Biological Mixture. United States Patent Office, #8,586,293 B2, issued November 19, 2013.
26. **Siegel D.L.:** Compositions, Methods, and Kits for Detection of an Antigen on a Cell and in a Biological Mixture. United States Patent Office, #8,617,805 B2, issued December 31, 2013.
27. **Siegel D.L.:** Methods for Isolation of Antibody Binding to Cells. United States Patent Office, #8,623,594 B2, issued January 7, 2014.
28. Payne A.S., Stanley J.R., **Siegel, D.L.**, Yamagami, J., Ishii, K. Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies. United States Patent Office #8,846,867, issued September 30, 2014.

29. Scholler N., Zhao A., **Siegel D.L.**, Coukos G.: Anti-TEM1 Antibodies and Uses Thereof. United States Patent Office, #9,556,272, issued January 31, 2017.
30. **Siegel D.L.**, Barbas C.F.: Phage Particle Diagnostic Reagents. United States Patent Office, #9,658,224 B2, issued May 23, 2017.
31. Scholler N., Zhao A., **Siegel D.L.**, Coukos G.: Anti-TEM1 Antibodies and Uses Thereof. United States Patent Office, #10,160,809, issued December 25, 2018.
32. **Siegel D.L.**, Milone, M.C., Kacir, S., Rader, C.: Treatment of cancer using GFR α -4 chimeric antigen receptor, United States Patent Office, #10,851,149 issued December 1, 2020.
33. Scholler N., Zhao A., **Siegel D.L.**, Coukos G.: Anti-TEM1 Antibodies and Uses Thereof. United States Patent Office, #11,078,285 B2, issued August 3, 2021.
34. Payne A.S., Stanley, J.R., **Siegel D.L.**, Ishii K: Isolation of Anti-desmoglein 1 Antibodies by Phage Display of Pemphigus Foliaceus Antibodies, PCT/US08/05924 (pending).
35. **Siegel D.L.**, Kacir S., Ostertag E., Zheng X.L.: Human Monoclonal Autoantibodies to ADAMTS13 and Uses Thereof, United States Patent Office, #11,597,778 B2, issued March 7, 2023.
36. Villa, C.H., Muzykantov, V.R., **Siegel, D.L.**, Greineder, C.: Fusion Proteins and Antibodies Targeting Human Red Blood Cell Antigens, United States Patent Office, #11,629,198 B2, issued April 18, 2023.
37. **Siegel, D.L.**, Bhoj, V., Rader, C., Goydel, R.: Humanized Anti-GDNF family alpha-receptor 4 (GFR-alpha-4) Antibodies and Chimeric Antigen Receptors (CARs), United States Patent Office, #11,802,159 B2, issued October 31, 2023.
38. **Siegel, D.L.**, Milone, M.C., Bhoj, V., Rader, C.: Treatment of cancer using GFR alpha-4 chimeric antigen receptor, United States Patent Office, #11,970,525B2, issued April 30, 2024.
39. Mason, N.J., **Siegel, D.L.**, Chester, N. Canine Monoclonal Antibodies Against Canine Cytotoxic T Lymphocyte Associated Protein 4 (CTLA-4), United States Patent Office, #12,110,331, issued October 8, 2024.
40. Hammers, C.M., **Siegel, D.L.**, Stanley, S.R.: Antibodies Against Basement Membrane Zone Adhesion Proteins BP180 and BP230, W02020072937A1 (pending).
41. Bhoj, V., Parvathaneni, K., **Siegel, D.L.**: Compositions and Methods of ADAMTS13 Chimeric Autoantibody Receptor Cells, 63/016,544, USA (pending).
42. Hua, X., He, X., Feng, Z., **Siegel, D.L.** Compositions and Methods for Retrieving Tumor-Related Antibodies and Antigens, PCT/US2019029333 (pending).
43. Hua, X., He, X., Feng, Z., **Siegel, D.L.** Compositions and Methods for Retrieving Tumor-Related Antibodies and Antigens, WO 2019/210155 A1 (pending).

44. **Siegel, D.L.**, Mason, N., Chester, N., Paz, K.: Fully Canine Anti-Canine PD-1 Antibodies and Uses Thereof (pending).
45. **Siegel, D.L.**, Sheppard, N.: Single Domain Camelid Antibodies to Human BCMA and Their Use in Chimeric Antigen Receptor (CAR) T Cells (pending)
46. **Siegel, D.L.**, Milone, M.C.: Novel CD19-Targeting Polypeptides and CD19-Directed Immunotherapies (pending)
47. Kurtis, J., **Siegel, D.L.**: Novel Therapeutic and Prophylactic Anti-Malarial Monoclonal Antibodies Targeting PfGBP130 (pending)

Commercialization of UPenn Intellectual Property:

2003 Founder, PhenoTech, Inc.

2018 Founder, Vetigenics, Inc.

2020 Founder, Verismo Therapeutics, Inc.

RESEARCH FUNDING**Current funding:**

| | |
|---|-------------------|
| T32-HL07775 (P.I. Siegel) NIH Transfusion Medicine Research Training Program Role: Principal Investigator | 7/1/94 - 6/30/25 |
| Verismo Therapeutics SRA (P.I. Milone and Siegel) Developing KIR-based CARs for Cancer Immunotherapy Role: Co-Principal Investigator | 8/11/21 – 8/11/25 |
| Precision Thyroid Cancer Therapy Catalyzer (Siegel) CAR-T Therapies for Medullary and Advanced Papillary Thyroid Cancers Role: Principal Investigator | 4/1/20 – 3/31/25 |
| R01 HL155106 (P.I. Muzykantov) Drug Targeting Role: Co-Investigator | 2/5/21-1/31/25 |
| 1P01CA214278-01 (P.I. June) NIH Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART-19 Role: Co-Investigator | 8/1/17 – 7/31/27 |
| Lymphoma/Leukemia Society (P.I. June) LLS SCOR “Pan-Heme” CAR: Anti-CD38 CAR T Cells for Myeloid, Lymphoid, and Plasma Cell Malignancies Role: Co-Investigator | 10/1/19 – 5/31/25 |
| R01 HL159256 (P.I. Muzykantov) NIH Blood Cell -Mediated Delivery of Thrombophylaxis Role: Co-Investigator | 7/1/21 – 6/30/26 |